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ABSTRACT OF THE DISSERTATION 
Bridging the translational gap between rodent and human pain research  
by 
Tayler Diane Sheahan 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, December 2017 
Professor Robert W. Gereau IV, Chair 
 
The treatment of chronic pain is an immense clinical and societal burden rooted in the 
ineffectiveness and adverse side effects of existing analgesics. Extensive efforts have been 
directed towards the development of novel pain therapies with maximal efficacy and minimal 
unwanted effects; however, putative therapeutic targets identified in preclinical rodent models 
rarely translate in clinical trials. The poor translational record of basic pain research findings has 
been attributed, in part, to the use of suboptimal rodent pain models and behavioral endpoints 
used to assess putative analgesics, as well as differences in the pharmacological profiles of 
rodents and humans. The work presented in this thesis aims to address these limitations.  
Human pain is defined as a complex sensory and emotional experience, yet rodent pain 
models have historically used reflex/withdrawal measures of hypersensitivity as the primary 
outcome. To address this limitation, the first study of this thesis evaluates more complex, 
voluntary behaviors as indicators of pain-like behavior in rodents. We found that inflammation 
and nerve injury minimally interfere with physical activity (voluntary wheel running, locomotion, 
and gait), social interaction, or anxiety-like behavior in mice, indicating that these voluntary 
behaviors are not reliable pain-related readouts across rodent injury models. As recent findings 
from other groups align with our results, we further conclude that in contrast to humans, 
changes in these voluntary behaviors are not characteristic of persistent pain in mice.  
 xi 
 
Although rodents and humans possess different pharmacological profiles, putative 
analgesics are oftentimes identified and exclusively evaluated in rodent tissues and/or pain 
models prior to entering clinical trials. In response to this translational gap, we recently 
developed a protocol to surgically extract dorsal root ganglia from deceased human organ 
donors and subsequently culture sensory neurons. In the second study of this thesis, we utilize 
human sensory neurons to assess the translational potential of targeting metabotropic 
glutamate receptors 2 and 3 (mGluR2/3), which have been identified as modulators of pain in a 
variety of rodent models. In mouse sensory neurons, we found that activation of mGluR2/3 
blocked inflammation-induced sensitization of the nonselective cation channel TRPV1. In 
contrast, this effect was not observed in human sensory neurons. These results indicate that 
mechanisms of peripheral analgesia are not entirely conserved across species. More broadly, 
our findings demonstrate that using human tissue to validate analgesic targets identified in 
rodents is an important step in the translational research process.  
  Due to poor pain relief from current pharmacological therapies, exercise has been 
explored as an alternative, nonpharmacological intervention for chronic pain. Indeed, exercise 
has been shown to improve patient pain ratings and functionality, albeit via largely unknown 
mechanisms. In the final study of this thesis, we evaluated whether voluntary exercise similarly 
reduced pain-like behavior in mice, with the goal of using a mouse model to elucidate the 
molecular mechanisms mediating clinical exercise-induced analgesia. However, we found that 
voluntary wheel running did not reduce pain-like behavior in common rodent models of 
inflammation and nerve injury. Previous preclinical studies of exercise-induced analgesia 
utilized forced exercise paradigms, and thus our findings suggest that voluntary and forced 
exercise may have different analgesic potential in rodents.   
Taken together, there are a variety of existing experimental limitations that can be 
addressed to increase the translatability of basic pain research. Based on our current findings, 
we conclude that voluntary rodent behavioral endpoints modeled off of the human chronic pain 
 xii 
 
experience have limited utility. In contrast, confirming preclinical findings in human tissue 
represents a promising approach to bridge the translational gap between rodent and human 
pain research.   
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Chapter 1 
 
Introduction to pain and experimental approaches in basic pain research 
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1.1 Chronic pain is a public health priority  
The treatment of chronic pain has been an immense societal and clinical burden for 
centuries.133 Recent estimates indicate that in the United States alone, chronic pain afflicts over 
100 million people and costs $635 billion annually with respect to health care expenses and 
productivity loss.60,75 These figures are likely to increase given the current aging population.67,125 
Common chronic pain conditions include low back pain, arthritis, migraine, and fibromyalgia. 
Further, chronic pain is often associated with diabetes, cancer, and chemotherapy.53,75,151 
Notably, these chronic pain conditions and others are frequently accompanied by physical 
disability and mood disorders, which further impair patient quality of life.49,64,76,120,156 Chronic pain 
is a nondiscriminatory disease: it affects populations irrespective of age, sex, ethnicity, and 
socioeconomic status (SES). However, higher incidence and severity of pain have been 
reported in women, older adults, and those of lower SES.15,53,61,125,151 Thus, given its 
pervasiveness and societal impact, chronic pain is gaining prominence as a public health 
priority.15,61  
Treating chronic pain has been an ongoing problem rooted in the ineffectiveness and/or 
adverse side effects of existing analgesics including opioids and nonsteroidal anti-inflammatory 
drugs (NSAIDs).17,54,55,75,143 Although opioids provide robust analgesia in some cases, the recent 
rise of opioid prescriptions for the treatment of chronic pain has manifested in an alarming 
increase in opioid addiction and misuse, which has become an epidemic in its own right.82,90 
Therefore, it is pressing that we develop new, efficacious therapies that could bypass the 
centrally mediated side effects of existing analgesics. In response to the poor pain relief from 
pharmacological interventions, exercise, mindfulness meditation, and pain management therapy 
have been explored as nonpharmacological interventions and have been shown to improve pain 
ratings and functionality in many cases, albeit via largely unknown mechanisms.38,58,170 
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However, as nonpharmacological/lifestyle interventions cannot be implemented by all chronic 
pain patients, new drug therapies are desperately needed.  
Over the past 50 years, substantial efforts have been directed towards the development 
of novel analgesics, yet there has been little improvement in clinical pain treatment 
options.55,86,116 Upon evaluation of years of repeated analgesic failure, the poor translational 
record of basic pain research findings has been attributed to a combination of limitations 
including 1) flawed clinical trial design and implementation, 2) differences in drug 
pharmacological profiles between rodents and human, and 3) the use of suboptimal rodent pain 
models and behavioral endpoints in assessing putative analgesics.101,116,158 Therefore, the 
development of efficacious chronic pain treatments will require an enhanced understanding of 
the mechanisms underlying pain processing, as well as improved pain research methodologies.  
 
1.2 Neurobiology of pain processing 
 Pain is defined as an unpleasant sensory and emotional experience associated with 
actual tissue damage, or described in terms of such damage.97 Pain is an important survival 
mechanism that warns an individual of potential bodily danger. Under normal physiological 
conditions, following injury or tissue damage, pain serves to protect the affected area from 
further damage until the injury has resolved. For example, tibial stress fracture is a common 
injury faced by long-distance runners that results from repeated microtrauma to the bone and 
produces tenderness of the leg.52,102 While injured, a runner is likely to experience a shift in pain 
response intensities such that a stimulus or activity that was not painful previously, such as 
walking, becomes perceived as painful, which is called allodynia.7,97 Further, stimuli or activities 
that are typically painful, such as applying pressure to the affected area, are perceived as 
exceedingly painful, which is referred to hyperalgesia.7,97 This pain serves as a warning 
mechanism to halt running until the injury has healed. In contrast, peroneal nerve entrapment 
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elicited by running causes prolonged pain that can continue even after surgical treatment.94 Pain 
that persists despite recovery from an injury (or in the absence of any injury) and no longer 
serves as a protective mechanism is referred to as chronic pain.  
The nervous system detects and processes noxious stimuli in a process called 
nociception (Fig. 1).97 Specialized sensory neurons of the peripheral nervous system referred to 
as nociceptors detect damaging stimuli via free nerve endings that innervate the skin and 
viscera.161 Noxious thermal, chemical, and mechanical stimuli act on high-threshold ion 
channels to cause nociceptor membrane potential depolarization.68 Sufficient depolarization 
elicits an action potential at the peripheral nerve terminal that is propagated along the axon, 
through the cell body located in the dorsal root ganglia (DRG), and to the central nerve 
terminals in the spinal cord dorsal horn (SCDH). In the SCDH, action potential propagation to 
central nerve terminals culminates in synaptic release of neurotransmitters and neuropeptides 
onto secondary SCDH neurons of the central nervous system.16,161  
Notably, in addition to the SCDH, nociceptive inputs originating at peripheral nerve 
terminals can also be transmitted back to the periphery (a phenomenon referred to as axon 
reflex48) or to the spinal cord ventral horn to mediate nociceptive withdrawal reflexes. Axon 
reflex arises when an action potential propagates locally along multiple peripheral branches of a 
single nociceptive afferent and causes the peripheral nerve terminals to release glutamate and 
peptides such as substance P and calcitonin-gene related peptide (CGRP).43,123,160 These 
events can drive neurogenic inflammation by promoting immune cell activation and 
vasodilation.66,99 Nociceptive withdrawal reflexes result when nociceptive inputs activate spinal 
interneurons that directly synapse on motor neurons within the spinal cord ventral  horn.136 
Motor neuron activation elicits a rapid withdrawal response from the painful stimulus, providing 
protection from further tissue damage, as when one places her hand on a hot stove.  
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Figure 1. Nociceptive and somatosensory circuits. A variety of stimuli can activate cutaneous fibers of 
dorsal root ganglia (DRG) neurons that project to the dorsal horn (DH) of the spinal cord. Within the DH, the 
central terminals of C and Aδ high threshold nociceptors (HT) and low-threshold mechanoreceptors (LTMR) 
project to distinct lamina and synapse on a variety of neuronal populations. Noxious inputs mediated by HT 
primary afferents terminate in superficial lamina I through the dorsal portion of inner lamina II (IIid) while 
innocuous inputs mediated by LTMRs terminate in the ventral portion of inner lamina II (IIiv) through lamina 
V. From the DH, inputs are relayed by ascending projection neurons to the thalamus and brainstem and 
then onto brain regions that mediate the sensory discriminative (light brown circles) and emotional-affective 
(dark brown circles) of pain. PFC, prefrontal cortex; ACC, anterior cingulate cortex; SI/SII, 
primary/secondary somatosensory cortex; AMY, amygdala; PAG, periaqueductal gray region, PB, 
parabrachial nucleus. Adapted from Peirs et al. 2016 with written permission from Rebecca Seal.126  
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From the SCDH, ascending projection neurons relay nociceptive inputs to the thalamus 
and brainstem, which further disseminate inputs to a variety of brain regions. To elaborate, 
thalamic nuclei extend projections to the somatosensory cortices, which encode nociceptive 
stimulus location, duration, and intensity. Thalamic nuclei also extend projections to the anterior 
cingulate and prefrontal cortices, which underlie emotional responses to noxious stimuli.2,7,16 
Projections from the parabrachial nucleus within the brainstem to the hypothalamus and 
amygdala mediate autonomic and affective responses to nociception, respectively.2 Additional 
inputs to brainstem nuclei such as the rostral ventral medulla and periaqueductal gray engage 
descending pathways that modulate nociceptive inputs at the spinal cord level.16 Together, 
activation of these brain regions and others – collectively termed the pain neuraxis – yields the 
complex, aversive sensory and emotional perception of pain. Dysregulation of nociceptive 
processing at any level of the pain neuraxis can produce chronic pain.68  
 
1.3 Molecular determinants of nociceptor functional diversity  
1.3.1 Sensory neurons are functionally diverse  
That we can perceive the nature of an acute noxious stimulus – that is hot, cold, 
mechanical, or chemical – has long intrigued scientists and physicians.138 After over a century of 
research, we now know that our ability to detect a wide range of noxious stimuli arises from the 
diversity of primary sensory afferents, which are classified based on axon diameter, extent of 
myelination, and conduction properties.132 Aβ afferents are large diameter, myelinated fibers 
with rapid conduction velocities that are broadly divided into two categories: low-threshold 
mechanoreceptors (LTMR) that convey innocuous mechanical inputs such as light touch and 
proprioceptors that encode body position and balance.1 Aδ afferents are medium diameter, 
thinly myelinated fibers that function as either LTMR or high-threshold (HT) nociceptors that 
carry noxious mechanical and/or thermal inputs, which are perceived as “fast pain”.132 The 
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majority of sensory neurons are slowly conducting C fiber afferents that are unmyelinated and 
small diameter.161 For the most part, C afferents are HT polymodal fibers that mediate “slow 
pain” in response to noxious thermal, chemical, and mechanical stimuli; however, C-LTMRs 
have also been identified in hairy skin.1,132,161 C fiber nociceptors can be further classified based 
on whether or not they express the neuropeptides CGRP and substance P, in which case they 
are termed peptidergic or nonpeptidergic C fibers, respectively. It has been suggested that 
these C fiber nociceptor subtypes are functionally distinct, with peptidergic nociceptors 
mediating responses to noxious heat, and nonpeptidergic nociceptors responding to noxious 
mechanical stimuli.27,103 In addition to these functional distinctions, the central terminals of 
primary afferent subtypes are somatotopically organized within the SCDH (Fig. 1). 
Neuroanatomical studies have revealed that Aδ and C fibers synapse in the superficial lamina I, 
outer lamina II, and the dorsal part of inner lamina II, whereas Aβ fibers synapse deeper in the 
ventral part of inner lamina II through lamina V18,174. In turn, these projections synapse onto 
unique subsets of secondary spinal cord neurons.126  
 
1.3.2 Transient receptor potential channels are the primary transducers of noxious stimuli   
The functional identity of nociceptors is governed by the expression of receptors and ion 
channels at the peripheral nerve terminal. Although there is a large cast of molecular mediators 
that contribute to nociception, the leading roles are played by sensory transient receptor 
potential (TRP) channels. TRP channels are a family of six-transmembrane domain, non-
selective cation channels with high Ca2+ permeability that are activated by a variety of 
exogenous and endogenous stimuli such as temperature, plant-derived irritants, toxins, acidity, 
and bioactive lipids.80,109  
TRPV1, TRPM8, and TRPA1 have emerged as the primary transducers of noxious 
stimuli. Briefly, TRPV1, formerly known as vanilloid receptor 1, is activated by temperatures > 
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42°C, chemical ligands including the pungent ingredient from spicy chili peppers called 
capsaicin, low extracellular pH, and bioactive lipids.26,106 The functional significance of TRPV1 in 
nociception was first demonstrated by impaired behavioral responses to noxious heat in mice 
lacking the receptor.25 Since this seminal discovery, TRPV1 has also been established as a 
mediator of inflammation-induced peripheral sensitization and neuropathic pain (further 
discussed below).8,25,41,81 The chief cold-sensitive ion channel within sensory neurons is TRPM8, 
which responds to cooling temperatures roughly < 25°C, as well as menthol and eucalyptol.105 
Analogous to TRPV1, mice lacking TRPM8 display decreased sensitivity to environmental 
cold.11,35,45 TRPA1, sensitive to garlic, cinnamon, and mustard oil, has also been proposed to 
mediate responses to cold temperatures < 15°C4,144; however, its role as an in vivo cold-sensor 
has been fiercely debated.92,104 While some studies of TRPA1-deficient mice show attenuated 
behavioral responses to noxious cold83,91, others find no effect of eliminating TRPA1.9,87,169 
Despite this controversy, sensory neuron TRPA1 is widely accepted as an important 
chemoreceptor for environmental irritants9,121, and has also been suggested to mediate and/or 
modulate mechanosensation.91,169 This finding is of particular interest, as the identity of the 
primary mammalian high-threshold mechanoreceptor remains an enigma.10,73,157 Other 
candidate mechanotransducers have been suggested, including Piezo proteins85,157, acid 
sensitive ion channels142, and TRPV457, yet further investigation regarding nociceptive 
mechanoreceptors is required.  
Notably, genetic knockout of TRPV1 or TRPM8 impairs, but does not fully abolish 
sensitivity to noxious heat or cold stimuli, respectively.11,25,35,41 Thus, functional redundancy of 
ion channels likely facilitates modality-specific detection of potentially harmful stimuli.7 
Nevertheless, much of our current understanding regarding the peripheral somatosensory 
processing of distinct modalities has resulted from studying sensory neurons expressing TRPV1 
or TRPM8, which are found in largely non-overlapping populations under uninjured conditions.88  
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1.4 Modulation of nociceptive input and peripheral sensitization   
Membrane-bound G-protein coupled receptors (GPCRs) and receptor tyrosine kinases 
(RTKs) play a critical role in the modulation of nociceptive inputs.7,28,161 Following injury, 
damaged neuronal and nonneuronal cells such as keratinocytes and infiltrating immune cells 
release a wide array of signaling molecules into the extracellular environment that comprise the 
“inflammatory soup”, including growth factors (nerve growth factor), peptides (CGRP, substance 
P, bradykinin), glutamate, prostaglandins, chemokines, and many others.132 These inflammatory 
mediators can directly influence sensory neurons by binding to their respective GPCR or RTK 
on peripheral nerve terminals, which activate multiple intracellular signaling cascades that have 
diverse downstream effects on nociceptors including 1) enhanced activity of ion channels and 
receptors that transduce noxious stimuli, 2) increased trafficking of nociceptive ion channels and 
receptors to the plasma membrane, 3) increased transcription and/or translation of nociceptive 
ion channels and receptors.7,109,161 These events culminate in increased responsiveness and 
decreased threshold of nociceptors, a form of neuronal plasticity termed peripheral 
sensitization.97 
Alterations in gene and protein expression caused by tissue insult and subsequent 
peripheral inflammation culminate in two important functional changes of injured nerve fibers 
and neighboring, intact fibers: phenotypic switching and ectopic activity.44,161 Aβ LTMR fibers 
undergo a phenotypic switch in which they express neuropeptides such as substance P de 
novo. In turn, Aβ LTMR fibers begin to convey both innocuous and noxious mechanical inputs, 
thereby expanding the proportion of primary afferents that convey nociceptive inputs to the 
SCDH.20,164 Behaviorally, Aβ phenotypic switching underlies tactile allodynia, as demonstrated 
by the rapid pain sensation experienced upon touching a cut or bruise, which could not be 
mediated by slow conducting C fibers.20,44 Further, “silent” C and Aδ fiber cutaneous nociceptor 
afferents insensitive to mechanical stimuli under physiological conditions gain mechanical 
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sensitivity after exposure to inflammatory mediators.108,140,163 In addition to phenotypic switching, 
membrane hyperexcitability due to increased expression of voltage-gated sodium channels and 
decreased levels of voltage-gated potassium channels causes Aβ, C, and Aδ sensory neurons 
to fire spontaneous action potentials as soon as hours or days after nerve injury.44,50,96,135,146 
Ectopic activity within intact fibers that comingle with injured fibers is believed to mediate 
spontaneous pain sensations.135,162 Taken together, peripheral sensitization broadens the 
repertoire of nociceptive inputs. Notably, these changes trigger and maintain central 
sensitization, thereby fostering the transition from acute to chronic pain.63,110,135 For this reason, 
blocking peripheral sensitization, with the idea of stopping pain at the source, remains an 
appealing therapeutic strategy. In fact, common drugs for pain relief such as NSAIDs work by 
reducing the production of proinflammatory and proalgesic mediators.7 Due to the plethora of 
extracellular inflammatory mediators, however, one might argue that directly reducing 
nociceptor sensitization rather than targeting a given inflammatory mediator may be a more 
effective way to reduce peripheral sensitization.  
 
1.5 TRPV1 is a key mediator of peripheral sensitization  
 Soon after the prominent role of TRPV1 in nociception was discovered, pain researchers 
found that TRPV1 similarly played a vital role in peripheral sensitization. For example, mice 
lacking the TRPV1 receptor fail to develop inflammation-induced heat hypersensitivity.25,41 
Likewise, pharmacological inhibition of TRPV1 can attenuate hypersensitivity to heat and/or 
mechanical stimuli in rodent models of nerve injury, diabetic neuropathy, and chemotherapy-
induced neuropathy.8,81,95,152 These behavioral observations spurred interest in TRPV1 as a 
putative peripheral analgesic target and drove investigation of the molecular mechanisms 
underlying TRPV1 modulation under physiological and pathological conditions.  
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The influx of calcium at nociceptor peripheral nerve terminals following TRPV1 activation 
has widespread intracellular effects. Sufficient plasma membrane depolarization can activate 
voltage-gated sodium channels and drive the firing of action potentials. Further, increased 
intracellular Ca2+ engages a variety of intracellular signaling cascades that influence ion channel 
function. Under physiological conditions, TRPV1 undergoes Ca2+-dependent desensitization 
upon dephosphorylation by calcineurin, a Ca2+/calmodulin-dependent phosphatase.150 
Conversely, Ca2+/calmodulin-dependent protein kinase II opposes Ca2+-dependent 
desensitization by maintaining phosphorylation of TRPV1.150 Thus, increased intracellular Ca2+ 
can bidirectionally modulate TRPV1 function.  
 Following tissue damage, TRPV1 is a prominent target of inflammatory mediators. As 
described above, inflammatory mediators influence ion channels at multiple levels, and TRPV1 
is no exception. Foremost, proinflammatory mediators sensitize TRPV1 by reducing the 
activation threshold and potentiating the response 
magnitude to suprathreshold stimuli.7,8,80,109 This 
occurs either by direct ligand (i.e. endovanilloids 
and protons) binding to TRPV1 at positive allosteric 
sites or indirect modulation of TRPV1 via 
intracellular second messenger signaling 
cascades.7,8,80,109 For instance, the proinflammatory 
mediator prostaglandin E2 (PGE2) binds to the 
PGE Gs-coupled GPCR subtypes EP3C and EP4, 
stimulating adenylyl cyclase and the cAMP/PKA 
pathway (Fig. 2).107,141 Subsequent PKA 
phosphorylation of TRPV1 increases channel 
conductance and decreases channel 
Figure 2. TRPV1 expressed on sensory 
neuron peripheral nerve terminals is 
sensitized by inflammatory mediators. 
Upon binding their receptor, inflammatory 
mediators such as PGE2 stimulate the 
cAMP/PKA pathway, leading to TRPV1 
phosphorylation (P) and sensitization. In 
rodents, activation of the Gi-coupled GPCRs 
mGlu2/3 suppresses TRPV1 sensitization by 
inhibiting the cAMP/PKA pathway and 
decreases nociceptor hyperexcitability.  
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desensitization.12,72,98,114,150 In addition to sensitization of TRPV1 channels already present in the 
plasma membrane, inflammatory mediators increase surface membrane expression of TRPV1. 
Nerve growth factor (NGF) has been shown to enhance membrane trafficking by inducing 
TRPV1 phosphorylation via Src family tyrosine kinases.78,109,171,172 Lastly, inflammation and 
nerve injury increase TRPV1 expression in sensory neurons. Retrograde transport of NGF from 
peripheral nerve terminals to DRG cell bodies increases TRPV1 translation.77,81 Notably, both 
enhanced TRPV1 protein in existing TRPV1+ neurons, as well as ectopic expression of TRPV1 
receptors in previously TRPV1-, myelinated afferents has been observed post-injury – another 
example of primary afferent phenotypic switching following peripheral sensitzation.71,129  
 The prevalent role of TRPV1 in peripheral sensitization rendered it a prime 
pharmacological target for pain relief. Over-the-counter, low-concentration capsaicin creams are 
marketed for pain relief, although the ability of these creams to cause analgesia compared to 
placebo has been contested.147 TRPV1 antagonists have also been widely explored in Phase I 
and II clinical trials; however, their clinical use has been limited largely due to hyperthermia 
resulting from activity at centrally expressed TRPV1 receptors.56,147 In cases of severe cancer 
pain, site-specific activation of TRPV1 by the extra-pungent capsaicin analog resiniferatoxin, 
which selectively causes excitotoxicity and ablation of TRPV1+ nociceptors while sparing other 
sensory afferents, has shown promise in both preclinical and clinical studies.19,69,100,147 However, 
resiniferatoxin is not a viable therapeutic strategy for all pain conditions. Although targeting 
TRPV1 for pain relief has been problematic, due to the presence of TRPV1 at peripheral nerve 
terminals and its essential role in peripheral sensitization, developing alternative strategies to 
modulate TRPV1 activity remains an enticing therapeutic strategy. Indeed, manipulating 
glutamate receptor intracellular signaling, which transmits and modulates nociceptive inputs, 
represents one such alterative strategy.  
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1.6 Glutamate transmits and modulates nociceptive inputs 
 Glutamate is the major excitatory neurotransmitter of the vertebrate nervous system and 
thus is pivotal to countless physiological and pathological processes including nociception, pain 
perception, and chronic pain. Glutamate activates two categories of receptors that are 
expressed throughout the pain neuraxis: ionotropic glutamate receptors (iGluRs) and 
metabotropic glutamate receptors (mGluRs).13,14,30,89,128 iGluRs are ligand-gated ion channels 
that mediate fast synaptic transmission, whereas mGluRs are GPCRs that modulate neuronal 
excitability through activation of secondary signal transduction pathways. In the periphery, 
glutamate is released from primary afferents as well as non-neuronal cells in response to tissue 
damage.43,74,123 Upon binding to receptors expressed on peripheral nerve terminals, glutamate 
contributes to the initiation of nociception as well as sensory neuron sensitization.7,14,84 
Glutamate also transmits and modulates nociceptive inputs within the SCDH. Specifically, once 
released from primary afferent presynaptic terminals, glutamate conveys nociceptive signals by 
binding postsynaptic iGluRs and mGluRs and also regulates subsequent neurotransmitter 
release by activating presynaptic mGlu autoreceptors.14,30,93 Following tissue damage, 
enhanced activity of iGluRs and mGluRs strengthens excitatory synapses and triggers activity-
dependent central sensitization.29,93 In supraspinal brain regions such as the thalamus, 
amygdala, anterior cingulate cortex, and prefrontal cortex, glutamate signaling relays and 
modifies the somatosensory, emotional, and cognitive aspects of pain.14,89 Aberrant glutamate 
receptor expression and signaling in these brain regions has been implicated in the 
development and maintenance of chronic pain.14,70,117  
 Pharmacological inhibition of iGluRs as a treatment for chronic pain has been explored 
in both preclinical and clinical studies. For instance, antagonists for the N-methyl-D-aspartate 
(NMDA) iGluR subtype were developed with the goal of blocking peripheral and/or central 
sensitization. Preclinical studies in rodents and horses demonstrated that NMDA antagonists 
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such as ketamine reduced pain-like behavior, suggesting that they would be viable clinical 
tools.70,117 However, psychotropic properties and dose-limiting negative side effects on learning 
and memory in a subset set of clinical trials discounted the widespread applicability of targeting 
NMDA receptors, and more broadly iGluRs, for chronic pain relief.32,70 Thus, mGluRs have 
emerged as favorable alternatives for modulating glutamate signaling in chronic pain states.   
 
1.6.1 Group II mGluRs suppress peripheral sensitization  
 The mGluRs are a family of seven transmembrane domain GPCRs distinguished by an 
N-terminus extracellular Venus-flytrap (VFT) domain and extracelluar cysteine rich domains 
(CRDs). The VFT domain houses the binding site for glutamate and other orthosteric ligands, 
whereas CRDs transmit activation signals to docked G protein complexes.159 The mGluR family 
has been subdivided into 3 groups based upon similarities in sequence, pharmacology, and 
intracellular signaling.36 Group I mGluRs (mGluR1 & 5) are Gq-coupled and lead to 
phospholipase C activation, in turn increasing neuronal excitability. In contrast, group II 
(mGluR2 & 3) and group III (mGluR 4,6,7, & 8) mGluRs are both Gi-coupled and suppress 
neuronal excitability by way of inhibiting adenylyl cyclase, as well as voltage-gated calcium 
channels, and activating potassium channels.36 
A variety of studies have evaluated group I, II, and III mGluRs in rodent models of 
inflammatory and neuropathic pain. Cumulative evidence suggests that pharmacological 
inhibition and activation of group I and group II/II mGluRs, respectively, reduces pain-like 
behavior.29,89,115 Though group III mGluRs are now gaining more interest, the group II receptors 
have been more extensively studied as putative analgesic targets. To elaborate, systemic 
pharmacological activation of group II mGluRs has been shown to decrease pain-like behavior 
in rodent models of both inflammatory and neuropathic pain.31,79,124,137,139 Interestingly, in 
uninjured rodents, group II agonists do not alter pain behavior,47,79,167 indicating that the 
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analgesic effect is specific to the sensitized state. While most group II ligands are not selective 
for mGluR2 versus mGluR3, genetic approaches have been used to distinguish whether activity 
of mGluR2, mGluR3, or both receptors underlies the analgesic properties of group II agonists. 
Importantly, analgesic efficacy of group II agonists persists in mGluR3-/-, but not mGluR2-/- mice, 
suggesting a greater role for mGluR2 than mGluR3 in pain regulation.168  
Following the observation that systemic mGluR2/3 activation reduces rodent pain-like 
behavior, the site of mGluR2/3 activation along the pain neuraxis required to elicit analgesia 
became an intriguing question. A variety of findings from our lab and others suggest that 
mGluR2/3 are well-positioned to depress pain transmission within sensory neurons. Foremost, 
pharmacological studies targeting sensory neuron mGluR2/3 via intraplantar hindpaw injections 
demonstrate that peripheral mGluR2/3 activation attenuates rodent nocifensive behavior.3,24,167 
Conversely, peripheral mGluR2/3 inhibition prolongs nocifensive behavior in rodent hindpaw 
inflammatory pain models, suggesting that endogenous activation of group II mGluRs is 
analgesic.24,167 Further, anatomical studies confirm expression of mGluR2/3 in rodent sensory 
neuron peripheral terminals, as well as DRG cell bodies and central projections.21–23,40 Lastly, in 
vitro studies of cultured rodent sensory neurons and skin-nerve preparations demonstrate 
functional expression mGluR2/3 in sensory neurons, as mGluR2/3 activation blocks sensory 
neuron hyperexcitability.23,40,165,166 Our recent studies in human sensory neurons confirm 
mGluR2/3 anatomical and functional expression across species.40 These findings are 
particularly exciting as mGluR2/3 now represent putative peripheral analgesic targets that could 
bypass centrally mediated side effects observed with existing analgesics. However, to remain 
viable analgesic targets, the molecular mechanisms underlying mGluR2/3-induced suppression 
of sensory neuron hyperexcitability require further investigation.  
There are a number of mechanisms by which mGluR2/3 activation within sensory 
neurons can reduce nociception. Rodent studies demonstrate that on sensory neuron central 
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terminals within the SC, mGluR2/3 activation negatively regulates neurotransmitter release onto 
secondary dorsal horn neurons.59 Further, on sensory neuron peripheral terminals innervating 
the skin, mGluR2/3 activation suppresses TRPV1 sensitization elicited by inflammatory 
mediators such as PGE2 by inhibiting adenylyl cyclase and the cAMP/PKA pathway (Fig. 
2).23,165–167 Whether the same mechanisms of peripheral analgesia are conserved in human 
sensory neurons is investigated in Chapter 3. 
 
1.7 Preclinical approaches to modeling and measuring pain and nociception:  
Translational opportunities 
 Much of our present understanding of nociception as well as physiological and 
pathological pain can be attributed to the use of preclinical animal models. Clinical studies are 
frequently complicated by human genetic diversity, differences in chronic pain etiologies, and 
lack of control over the plethora of environmental conditions that can influence pain perception 
and pharmacological outcomes such as diet and lifestyle.68 In many ways, rodent models 
minimize these complications.  
 We now have great command over rodent genetics whereby inbred strains allow for 
assessment of nociception and pain manipulations in genetically identical test subjects and 
molecular tools allow us to genetically modify mice with relative ease. For instance, the Cre-
LoxP recombination system permits cell-type specific deletion of a gene of interest and analysis 
of the consequences of such deletions.118 We have previously used this system to eliminate 
expression of Ret, the GDNF family of ligands receptor, exclusively from nociceptors and 
demonstrated that Ret is required for the survival and normal function of nonpeptidergic 
nociceptors.62 Besides nociceptor physiology, genetic recombination systems have allowed us 
to probe within the spinal and central circuits that underlie pain processing with neuron subtype 
specificity that was unfathomable only three decades ago.149  
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1.7.1 Rodent pain models and traditional readouts of pain-like behavior 
In addition to genetic control, rodent injury models allow us to investigate injuries with 
standardized onset, etiology, and location in a controlled environment. Common rodent acute 
and persistent pain models, including those utilized within the present manuscript, often involve 
injury to the hindpaw or the nerves innervating the hindpaw. For instance, proinflammatory 
agents such as formalin or Complete Freund’s Adjuvant are injected subdermally into the 
plantar surface of the hindpaw to model acute and persistent inflammation, respectively.130 
Nerve injury models including the spared nerve injury model involve either ligation or 
compression of the nerve or nerve roots comprising the sciatic nerve.42,46 Although these rodent 
pain models represent convenient, controlled manipulations for researchers to investigate 
putative pharmacological targets for pain relief, their relevance to human chronic pain conditions 
has been questioned.33,101,112 The incorporation of diabetic- and chemotherapy-induced 
neuropathy as well as metastatic bone cancer pain models represents one attempt to increase 
the clinical applicability of preclinical pain research33,127; however these models do not fully 
recapitulate human disease and have not replaced traditional inflammation and nerve injury 
models.   
The clinical relevance of traditional pain behavioral measures has also received great 
scrutiny. Preclinical pain researchers have historically relied on measures of nociceptive 
withdrawal reflexes: a mechanical, heat, or cold stimulus is applied to the plantar surface of the 
hindpaw and the withdrawal response threshold and/or latency is reported. Injury-induced 
hypersensitivity is indicated by reduced response thresholds/latencies. In some injury models 
such as the formalin test, spontaneous nocifensive behaviors including licking and lifting of the 
hindpaw can be quantified. Withdrawal reflex and spontaneous nocifensive behavioral 
endpoints encompass the somatosensory component of pain. However, the human pain 
experience is a complex sensory, cognitive, and emotional experience, and the primary 
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outcome in clinical trials is often improved health-related quality of life measures rather than 
improved pain ratings.122,145 This mismatch between rodent and human pain measures is 
proposed to contribute to the poor translational record of putative analgesics identified in rodent 
models.6,33,34,112,113,131,134,148 Thus, the development of voluntary and quality of life behavioral 
measures in rodents that reflect the complexities of human pain could improve the translation of 
basic pain research.  
 
1.7.2 In vitro approaches towards understanding nociception  
 In vitro rodent models have provided an excellent foundation in our understanding of the 
molecular mechanisms that mediate nociception and peripheral sensitization. For example, 
cultured primary sensory neurons and semi-intact nerve preparations can be used to identify 
neuronal subpopulations that convey distinct somatosensory modalities.5,65,153,154 These insights 
are certainly informative, yet despite the evolutional significance of pain, rodents are not small, 
fuzzy people. Rather, rodents and humans undoubtedly possess distinct pain-mediating 
molecular palettes. The voltage-gated sodium channel NaV1.7 represents one notable example 
of species differences in nociceptor physiology. Humans lacking the voltage-gated sodium 
channel NaV1.7 are unable to detect any form of pain, whereas only some pain phenotypes are 
lost in nociceptor-specific NaV1.7-conditional knock out mice.7,37,111,119 Therefore, verifying that 
molecular targets/mechanisms identified in rodents are conserved in human tissue prior to 
conducting clinical studies could immensely improve the translational record of preclinical 
analgesics. Limited access to human tissue has unfortunately obstructed these investigations. 
To address this limitation, we and others have sought access to human sensory neurons.39,51,173 
In collaboration with Mid-America Transplant, we recently established a protocol to surgically 
extract human DRG from deceased organ donors and culture sensory neurons from these 
 19 
 
donors.155 Thus, we now have the exciting and unique opportunity to study human nociceptor 
anatomy and physiology.  
 
1.8 Approaches for bridging the translation gap between rodent and human pain research 
 In summary, traditional rodent pain models and behavioral measures provide an 
important foundational understanding of mechanisms of nociception and pain manipulations. 
However, to improve the translational record of preclinical analgesics and tackle the public 
health issue of treating chronic pain, it is critical that we bridge the translational gap between 
rodent and human pain research. The present manuscript describes three studies in which I aim 
to increase the translatability of basic pain research. First, I investigate a variety of voluntary 
behaviors as read outs of persistent pain in mice (Chapter 2). Second, I utilize human and 
mouse sensory neurons to determine whether the mechanism of mGluR2/3-induced 
suppression of sensory neuron sensitization is conserved across species (Chapter 3). Finally, I 
evaluate whether voluntary exercise in rodents can be used as a model to elucidate the 
mechanisms that underlie the clinical observation that exercise is an effective 
nonpharmacological intervention for pain relief (Chapter 4).  
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Chapter 2 
Inflammation and nerve injury minimally affect mouse voluntary behaviors 
proposed as indicators of pain 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter contains the manuscript: 
Sheahan TD, Siuda ER, Bruchas MR, Shepherd AJ, Mohapatra DP, Gereau RW, IV, Golden 
JP: Inflammation and nerve injury minimally interfere with mouse voluntary behaviors proposed 
as indicators of pain. Neurobiology of Pain 2:1-12, 2017. doi: 10.1016/j.ynpai.2017.09.001 
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2.1 Abstract 
 
It has been suggested that the lack of rodent behavioral assays that represent the 
complexities of human pain contributes to the poor translational record of basic pain research 
findings. Clinically, chronic pain interferes with patient mobility and physical/social activities, and 
increases anxiety symptoms, in turn negatively impacting quality of life. To determine whether 
these behaviors are similarly influenced by putative pain manipulations in rodents, we 
systematically evaluated wheel running, locomotion, gait, social interaction, and anxiety-like 
behavior in models of inflammation and nerve injury in adult C57BL6/J male mice. We 
demonstrate that inflammation and nerve injury differentially affect voluntary behaviors while 
mice are hypersensitive to mechanical stimuli. Bilateral Complete Freund’s Adjuvant (CFA)-
induced inflammation transiently suppressed wheel running and locomotion and also induced 
gait deficits. In contrast, spared nerve injury (SNI) altered gait and impaired gross motor 
coordination. SNI-induced gait changes were not reversed by the analgesic PD123319, an 
angiotensin II type 2 receptor antagonist, and are therefore likely to be motor-related rather than 
pain-related. Neither CFA nor SNI significantly altered social interaction or elicited general 
anxiety-like behavior. Our findings suggest that in contrast to humans, mobility and 
physical/social activities are minimally altered, if at all, in mice following inflammation or nerve 
injury.  
 
 
 
 
 
 
 
 
 34 
 
2.2 Introduction 
Chronic pain is an immense clinical and societal burden with largely unsatisfactory 
pharmacological treatment options.22,29,55 Considering the rising opioid epidemic, it is pressing 
that we develop new, efficacious drug therapies. However, over the past 50 years, the 
development of novel analgesics has been hindered by the high failure rate of clinical trials.32,48 
The lack of rodent pain assays that encompass the complexities of human chronic pain is 
thought to contribute to the poor translational record of preclinical analgesics.2,10,13,37,43,45,65,72,85,88 
Clinically, chronic pain is characterized by sensory, affective, and emotional changes that 
negatively impact quality of life.41 To this end, outcomes of interest in clinical trials for pain relief 
are primarily improved health-related quality of life and functionality, rather than nociceptive 
thresholds.55,84 However, preclinical pain research has historically relied on mechanical and 
thermal hypersensitivity as a primary outcome in rodent pain models, which represents only one 
component of human chronic pain. To address this translational gap, substantial efforts have 
been directed towards the assessment of voluntary behaviors and quality of life measures in 
rodent pain models that better reflect how pain impacts the lives of patients.2,43,85  
Clinical studies demonstrate that chronic pain reduces quality of life in part by impairing 
mobility as well as physical and social activities, and increasing anxiety symptoms.20,25,27,30,53,77,90 
Accordingly, one goal of preclinical pain researchers is to develop and utilize measures of pain-
related suppressed and evoked behaviors.52 However, preclinical studies evaluating the effects 
of inflammation and nerve injury on rodent gait, locomotion, social interaction, and anxiety-like 
behavior have yielded conflicting results. In some cases, inflammation and nerve injury have 
been shown to alter gait8,14,46,59–61, suppress general locomotion and voluntary wheel 
running12,24,31,42,60,61,82,83, reduce social interactions56,64, and/or induce anxiety-like 
behavior17,36,50,62,70,92; however, in other cases, these behaviors were unchanged by persistent 
pain.9,23,47,73,87 These conflicting results may be the product of differences in study design with 
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respect to species, injury model, behavioral paradigms, etc. Thus, whether these endpoints are 
valid measures of rodent pain-related behavior remains unresolved.  
In the present study, we systematically evaluated voluntary wheel running, locomotion, 
gait, social interaction, and anxiety-like behavior in two commonly used mouse models of 
persistent pain: Complete Freund’s Adjuvant-induced inflammation and the spared nerve injury 
model of neuropathic pain. When appropriate, we tested for correlations between changes in 
voluntary behavior and mechanical hypersensitivity, a widely used stimulus-evoked/reflexive 
endpoint. Further, to determine whether changes in voluntary behaviors were pain-related, we 
tested if they could be reversed with an analgesic. We utilized the angiotensin II type 2 receptor 
antagonist PD123319, a promising candidate analgesic that has been shown to be effective in a 
variety of rodent peripheral nerve injury models49,74,79,80, and is related to the compound 
EMA401 that has shown efficacy in a phase II clinical trial for neuropathic pain.66  
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2.3 Materials and Methods 
Experimental Animals 
Animals were cared for in compliance with the National Institutes of Health guidelines 
and approved by the Animal Studies Committee of Washington University in St. Louis (Protocol 
Numbers 20130147, 20160097). Experiments were predominantly conducted on adult 
C57BL/6J male mice bred in house using breeding pairs from Jackson Labs. (Bar Harbor, 
Maine). One cohort of adult experimental animals was obtained directly from Jackson Labs and 
allowed to acclimate to our animal housing facility for at least 1 week before initiating behavioral 
testing. Mice were housed with up to 4 cagemates in the animal facility under a 12-hour (hr) 
light/dark cycle (6AM-6PM) and provided food and water ad libitum. Cages were lined with 
corncob bedding. Behavioral experiments began when mice were 7-9 weeks of age. Throughout 
experiments, animals were regularly monitored for general health and weighed weekly. At the 
conclusion of each study, mice were euthanized using a rodent ketamine euthanasia cocktail.  
 
Experimental Models of Pain 
Throughout all surgical procedures, mice were anesthetized with 2% isofluorane.  
Intraplantar Complete Freund’s Adjuvant (CFA) was used as a model of persistent inflammatory 
pain. Mice received a single bilateral intraplantar hindpaw injection of 20 µL undiluted CFA  (1 
mg/mL; Sigma, St. Louis, MO). Control mice were similarly injected bilaterally with 20 µL of 
0.9% sterile saline. Behavioral testing began as soon as 4 hr post injection. 
Unilateral spared nerve injury (SNI) was performed as described previously.16,67,73 Akron 
lidocaine hydrochloride jelly (2%; Vessel Medical, Greenville, SC ) was applied topically to the 
incision site. The three branches of the sciatic nerve were exposed by separating the biceps 
femoris muscle, and the common peroneal and tibial branches were ligated with silk suture and 
cut distal to the ligation, taking care not to manipulate the sural nerve. Sham operation 
comprised a skin incision over the biceps femoris muscle. For all operations, the skin incision 
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was closed with staples that were removed on postoperative day (POD) 7, once wounds had 
healed. Allowing time for post-operative recovery, behavioral testing began no sooner than POD 
4. Upon completion of behavioral studies, SNI mice were dissected to confirm that the sural 
nerve was not included in or damaged by the ligation surgery. If the sural nerve was not intact, 
animals were excluded from the study (4% of SNI mice).  
 
CFA-Induced Paw Edema 
Paw thickness (in millimeters) was measured using 150 mm stainless dial calipers 
(Chicago Brand, Medford, OR). Paw thickness was measured at baseline, as well as post-
intraplantar injection of either CFA or saline.  
 
Behavioral Studies 
For each experimental cohort, animal groups were randomized and the experimenter 
was blind to injury and/or drug treatment groups until the completion of data analysis. Unless 
otherwise specified, prior to behavioral testing, mice were acclimated to the testing apparatus 
(von Frey) or the testing room within their homecages (voluntary wheel running, open field, 
rotarod) for 1-2 hr with low-level white noise. In cases where both baseline and post-injury 
measurements were made, data for each mouse is reported as normalized to baseline (von 
Frey, voluntary wheel running, gait analysis). Experiments were performed during the light cycle 
between 8 AM and 5 PM.  
Sample sizes for each behavioral endpoint were modeled off of group sizes required to 
observe physiologically significant behavioral effects in previously published rodent studies of 
voluntary behaviors.60,61,76 Where correlation analyses were planned, additional animals were 
tested to meet the adequate sample size to make comparisons between behavioral endpoints. 
Cohorts were comprised of 10-15 mice from a single source (either in house or Jackson Labs). 
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At least two cohorts of animals were tested for each behavioral endpoint to obtain the 
appropriate sample size and evaluate whether injury- or drug-induced changes produced similar 
effects across cohorts. All CFA cohorts were bred in house and all but one SNI cohort 
(evaluated in von Frey, voluntary wheel running, and the social interaction assay) was bred in 
house. Similar SNI-induced behavioral effects were observed across cohorts regardless of the 
animal source.  
 
Mechanical Sensitivity (von Frey) 
Mechanical sensitivity was measured using the up-down method of the von Frey test.7 
Prior to baseline behavioral testing, mice were habituated to the elevated mesh grid in 
Plexiglass boxes for 2 hr/day for 2 days. On testing days, calibrated filaments (North Coast 
Medical Inc., Gilroy, CA) were applied to the plantar surface of the hindpaw. In SNI studies, 
baseline and post-operative mechanical sensitivity was measured on the lateral aspect of the 
hindpaw.18 In all studies, 3 trials were conducted on each paw, with at least 5 min between 
testing opposite paws, and at least 10 min between testing the same paw. Mechanical 
withdrawal thresholds of each paw were calculated by averaging values obtained across trials. 
We established a von Frey threshold inclusion criterion to ensure that an adequate dynamic 
range existed for detecting mechanical hypersensitivity following injury. In order for an animal to 
be tested post-injury, baseline thresholds had to be greater than or equal to 0.20 g. Of the total 
number of mice that underwent baseline testing, 98% of CFA mice (tested on the center of the 
paw) and 78% of SNI mice (tested on the lateral aspect of the paw) met the inclusion criterion.  
 
Voluntary Wheel Running 
Voluntary wheel running was quantified using wireless low-profile running wheels (Med 
Associates, Fairfax, VT). To reduce environmental novelty, mice were first acclimated to 
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individual cages with locked running wheels for 2 hr/day for 2 days. Running wheels were then 
unlocked for baseline behavioral testing. Distance travelled was recorded for 2 hr without the 
experimenter in the room. Mice were classified as non-runners if they ran less than 200 m 
during the baseline session and were not tested for voluntary wheel running post-injury. Of all 
animals that underwent baseline testing, 10% were non-runners. Wheel running experiments 
were conducted during the light cycle between 11 AM and 1 PM. 
 
Social Interaction  
Social interaction was measured using a social approach assay described previously.76 
Room lighting was ~200 lux. The black, plastic testing arena (52.5 L X 25.5 W X 25.5 H cm), the 
bottom of which was covered with corncob bedding, consisted of two-chambers, each 
containing an inverted metal, mesh pencil cup. One pencil cup was arbitrarily designated to lie 
within the social zone. The social zone was defined as a circle equal to twice the diameter of the 
pencil cup. Prior to testing, mice were acclimated to a silent room in their homecages for 1 hr. In 
the baseline trial, the test mouse moved freely within the arena for 10 min once the 
experimenter left the room. EthoVision XT video tracking software (Noldus, Cincinnati, OH) was 
used to monitor animal movement and quantify time spent within the social zone. Following the 
baseline trial, the test mouse was returned to its homecage for 30 min. An unfamiliar, age-, sex-, 
and strain-matched conspecific stimulus mouse was then placed beneath the social zone pencil 
cup. In the social trial, the test animal was reintroduced into the arena for 10 min and the time 
spent in the social zone was recorded. Test mice could see, hear, and smell, but not physically 
interact with the stimulus mouse within the pencil cup. Social interaction scores were 
determined by dividing the amount of time the test mouse spent in the social zone during the 
social trial by the amount of time the test mouse spent in the social zone during the baseline 
trial.  
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Locomotor Activity and Anxiety-Like Behavior (Open Field) 
Locomotor activity was quantified in an open field chamber equipped with a Versamax 
Animal Activity Monitoring System (AccuScan Instruments Inc., Columbus, OH) under normal 
laboratory light (~770 lux). Following acclimation, mice were individually placed into the center 
of the open field and allowed to explore the chamber for 1 hr once the experimenter left the 
room. Total distance traveled and time spent moving were calculated for the 42 L X 42 W X 20 
H cm chamber. Anxiety-like behavior was evaluated by quantifying the percentage of time spent 
in the center zone of the open field arena over the 1 hr testing period. The center zone was 
defined as a square comprising 40% of the arena. As open field activity is largely driven by 
exploratory behavior of a novel environment15, mice were only tested in the open field once. 
Thus, open field activity across multiple post-CFA timepoints was acquired from separate 
cohorts of mice. 
 
Gross Motor Function (Rotarod) 
Motor coordination and balance was determined using an accelerating rotarod (Ugo 
Basile, Varese, Italy). First, a training session involving 120 s on a non-accelerating rotarod was 
conducted, followed by 1 hr of rest with mice in their homecages. Then 5 consecutive trials with 
5 min rest intervals between trials were performed. Latency to fall as the rotarod accelerated 
from 4 to 40 rpm in 30 s increments over 5 min was recorded.  
 
Catwalk Automated Gait Analysis  
Gait analysis was performed using the Catwalk XT 10.5 system (Noldus, Cincinnati, 
OH). Briefly, the Catwalk XT system consists of an elevated, enclosed glass platform (130 L X 7 
W cm) and a high-speed camera (GEViCAM GP-2360C). Green light is internally reflected into 
the glass platform and light is emitted downward only when pressure is placed upon the glass 
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(i.e. by an animal’s paw). The high-speed camera detects emitted light intensity per pixel, and 
the accompanying Catwalk XT software acquires and analyzes gait parameters. Gait analysis 
data were acquired using the following experimental settings: camera gain: 13-15 dB, green 
light intensity threshold: 0.12, run duration: 0.5-5.0 s, run maximum variation: 60%. In some 
cases, the ipsilateral hindpaw of SNI mice was not detectable using these experimental settings 
and these animals were ineligible for analysis.  
The day prior to baseline behavioral testing, mice were acclimated to the Catwalk 
platform over two 15 min sessions separated by 30 min. On testing days, mice were habituated 
to the testing room for at least 30 min and behavioral testing was conducted in a completely 
dark, silent room. Mice voluntarily traversed the enclosed glass platform. At each testing 
timepoint, 4 compliant runs were obtained and averaged per mouse. Postoperative Catwalk 
testing on SNI animals began after surgical staples were removed on POD 7, as the staples 
could have subtle effects on gait.   
Parameters obtained and reported from Catwalk gait analysis include: 
Paw pressure (max contact, mean intensity): Average print intensity (a.u.) when the paw 
is making maximum contact with the glass.  
Run speed: Average body speed (cm/s) 
Stance phase: Duration (s) that paw is in contact with the glass platform 
Swing phase: Duration (s) that paw is not in contact with the glass platform  
Step duration: Sum (s) of stance and swing phase 
Fraction stance phase: Stance phase divided by step duration 
Fraction swing phase: Swing phase divided by step duration  
Maximum contact area: Maximum area (cm2) of the paw that contacts the glass platform  
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Drugs and Drug Administration 
PD123319 ditrifluoroacetate (Tocris, Minneapolis, MN), also known as EMA200, was 
dissolved in 0.9% sterile saline and injected at 10 mg/kg, i.p. Vehicle controls were injected with 
an equal volume of saline. Notably, previous studies demonstrate that systemic administration 
of 10 mg/kg PD123319 attenuates hypersensitivity without impairing motor coordination in the 
rotarod test.58,79 The effects of PD123319 on mechanical hypersensitivity and Catwalk hindpaw 
pressure were evaluated over 3 testing sessions per behavioral assay: pre-drug, drug, and post-
drug sessions. Each testing session was separated by 24-48 hr. All experiments evaluating the 
effects of PD123319 were performed between POD 7 and POD 41, when SNI mice were known 
to be hypersensitive. Mechanical hypersensitivity testing sessions were performed on either 
POD 12-16 or 26-30 and results from these timepoints were pooled together. Catwalk hindpaw 
pressure testing sessions were performed on POD 9-12. Behavioral testing took place 1.5-2.5 
hr post injection, the time frame at which peak analgesia with respect to mechanical 
hypersensitivity has been reported.74,79  
 
Statistical Analyses 
All data were analyzed using Excel (Microsoft, Redmond, WA) and Prism (GraphPad 
Software, Inc., La Jolla, CA) and are presented as mean ± SEM. Significance was defined as 
p<0.05 a priori. Post-injury withdrawal thresholds, running distances, Catwalk gait parameters, 
and paw thickness are normalized to baseline values measured prior to inflammation or nerve 
injury. Figure legends indicate the group size and statistical test for each experiment. Briefly, 
data comparing the effect of CFA or SNI on paw thickness, body weight, and behavior over time 
were analyzed with a Student’s t-Test and Holm-Sidak correction for multiple comparisons, 
when appropriate. The effects of PD123319 on SNI-induced behavioral changes were analyzed 
using a two-way repeated-measures (RM) ANOVA, post-hoc Student’s t-Tests, and Sidak 
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correction for multiple comparisons. Pearson correlation coefficients were determined to 
evaluate the relationship between CFA- or SNI-induced mechanical hypersensitivity and 
changes in voluntary behaviors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
2.4 Results 
CFA induced paw edema and mechanical hypersensitivity 
To determine the effects of persistent inflammation on rodent stimulus-evoked and 
voluntary behaviors, we utilized the intraplantar Complete Freund’s Adjuvant (CFA) model of 
inflammatory pain.28,63 Following bilateral intraplantar injections of CFA, we observed significant 
thickening of the hindpaws that persisted for at least 14 days relative to saline-injected controls 
(Fig. 1A). Intraplantar CFA is known to produce robust hypersensitivity that persists for at least 
1-2 weeks.12,28,63,78 Similarly, we observed a significant reduction in hindpaw mechanical 
withdrawal thresholds in CFA mice compared to saline mice (Fig. 1B). Mechanical 
hypersensitivity was detectable on post injection day (PID) 0 (~4 hr after the injection) through 
PID 9. Interestingly, CFA-induced mechanical hypersensitivity recovered by PID 14 despite 
persistent paw edema.  
 
CFA suppressed voluntary wheel running 
To determine whether persistent inflammation alters voluntary behaviors, we tested mice 
between PID 0 and 7, when CFA-induced mechanical hypersensitivity was most robust. We first 
assessed whether inflammation suppressed voluntary wheel running. In order to decrease the 
likelihood of exercise-induced analgesia11,33, wheel running distances were quantified every 
other day beginning 1 day after injection. We initially tested whether unilateral intraplantar CFA 
suppressed voluntary wheel running. In alignment with a previous report12, unilateral CFA did 
not affect wheel running activity compared to saline (data not shown). We next tested whether 
bilateral CFA affected voluntary wheel running. Relative to saline, bilateral CFA produced a 
significant reduction in voluntary wheel running on PID 1 (Fig. 1C). Wheel running of CFA mice 
began to recover on PID 3 and reached that of saline mice by PID 7, despite continued CFA-
induced   mechanical   hypersensitivity  through PID 9.  The time  course of  recovery from CFA- 
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induced suppression of voluntary wheel running closely resembles that reported by 
others12,24,31,60, suggesting that the effects of CFA on voluntary wheel running are consistent and 
reproducible. As bilateral CFA administration was required to observe suppression of wheel 
running, all subsequent investigations of the effects of inflammation on voluntary behavior were 
conducted using bilateral CFA injections. 
CFA did not affect social interactions  
 To determine whether persistent inflammation decreased social interaction, we used a 
behavioral model of social approach.75,76 Social interaction scores of CFA mice with an 
unfamiliar age-, sex-, and strain-matched conspecific were equivalent to saline mice on PID 2 
(Fig. 1D-F). Our findings support previous work demonstrating that acutely after injection, CFA 
does not affect social interactions of mice that are hypersensitive to mechanical stimuli.36 
  
CFA induced gait alterations 
 To evaluate whether bilateral CFA elicited static and/or dynamic gait deficits, we utilized 
the Catwalk XT gait analysis system. With respect to static gait parameters, compared to saline, 
Figure 1. Bilateral CFA suppressed locomotion and altered gait, but did not affect social interaction 
or anxiety-like behavior. (A) Bilateral intraplantar injection of Complete Freund’s Adjuvant (CFA) 
produced significant paw edema that persisted for at least 14 days compared to injection of saline (n=10-
17/group). (B) CFA mice displayed a significant reduction in mechanical hindpaw withdrawal thresholds as 
soon as 4 hr post injection (day 0) through post injection day (PID) 9 compared to saline mice (n=10-
17/group). (C) Voluntary running was significantly reduced by CFA on PID 1 compared to saline (n=11-
23/group).  Representative heatmaps from the social interaction test of (D) saline and (E) CFA mice in the 
absence (top) and presence (bottom) of an unfamiliar conspecific. Scale bar indicates total time spent in 
each arena location. Presence within circles reflects time spent atop the pencil cups. (F) Social interaction 
scores were equivalent between CFA and saline mice on PID 2 (n=12/group).  (G, H) Catwalk gait analysis 
demonstrated that CFA significantly decreased hindpaw pressure though PID 3 compared to saline, yet no 
changes in forepaw pressure were observed (n=12/group). (I) Despite the paw edema of CFA mice, 
hindpaw contact area with the Catwalk platform was equivalent between CFA and saline mice. (J, K, L) 
CFA caused a significant reduction in run speed across the Catwalk platform on PID 1; however no 
differences in stance phase or swing phase were observed between CFA and saline mice. (M, N) CFA 
significantly reduced distance moved and time spent moving in an open field compared to saline on PID 2 
(n=11-13). (O) CFA mice did not display anxiety-like behavior in an open field compared to saline mice at 
either timepoint tested. Data are presented as mean ± SEM. Student’s t-Test, Holm-Sidak correction for 
multiple comparisons, when appropriate. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, as compared with 
saline mice. 
 47 
 
CFA significantly reduced hindpaw pressure through PID 3 (Fig. 1G) without altering forepaw 
pressure (Fig. 1H). Paw pressure was determined at the point of maximum contact of the paw 
with the Catwalk platform. Therefore, we evaluated whether CFA-induced paw edema could be 
affecting hindpaw pressure by increasing maximum hindpaw contact area. However, compared 
to saline, CFA administration did not significantly alter hindpaw maximum contact area (Fig. 1I).  
 With respect to dynamic gait parameters, CFA significantly decreased run speed on PID 
1 compared to saline (Fig. 1J). Many gait parameters are dependent on run speed.3 Therefore, 
stance phase and swing phase were calculated as a fraction of the total step duration, the 
combined duration of the stance and swing phases. No changes in stance phase or swing 
phase were observed following CFA (Fig. 1K, 1L). In contrast to these findings, previous reports 
of rodent gait analysis following unilateral intraplantar CFA demonstrate a broader effect of 
inflammation on gait. For instance, reduced stance phase and prolonged swing phase of the 
injected hindlimb have been proposed to reflect pain avoidance behavior.14,59,60 In our studies, 
however, bilateral injury likely precluded the ability to observe possible inflammation-induced 
avoidance behaviors in hindpaw gait parameters. Collectively, our findings demonstrate that 
bilateral CFA produces transient, yet significant changes in a subset of static and dynamic gait 
parameters.  
 
CFA induced changes in open field behavior   
 To determine whether persistent inflammation affected locomotor and/or anxiety-like 
behavior of mice, open field activity was evaluated. On PID 2, CFA mice displayed significantly 
decreased distance moved and time spent moving within the open field compared to saline mice 
(Fig. 1M, N). These locomotor deficits were no longer present in mice tested on PID 5. Similarly, 
Refsgaard et al. report that open field locomotor behavior is unchanged on PID 4 following 
unilateral intraplantar CFA.62 In the open field test, anxiety-like behavior is expressed as a 
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reduction in the proportion of time spent in the center zone of the open field compared to a 
control condition. In our studies, time spent in the center of the open field was comparable 
between CFA and saline mice on all testing days (Fig. 1O). These results suggest that mice do 
not exhibit anxiety-like behavior in the open field after inflammation, and are supported by 
previous findings.36,87   
 
SNI induced mechanical hypersensitivity 
We next tested whether nerve injury also caused changes in voluntary behavior. To 
determine the effects of nerve injury on rodent stimulus-evoked and voluntary behaviors, we 
utilized the spared nerve injury (SNI) model of neuropathic pain. SNI has been shown to 
produce prolonged mechanical hypersensitivity in the lateral aspect of the hindpaw.16,73,87 We 
similarly observed a significant reduction in hindpaw mechanical withdrawal thresholds of SNI 
mice compared to sham-operated mice by postoperative day (POD) 7, which persisted through 
at least POD 40 (Fig. 2A).  
 
SNI did not suppress voluntary wheel running or social interaction 
To test whether nerve injury suppressed voluntary wheel running, running distances 
were quantified at multiple postoperative timepoints between POD 5 and POD 41. At each 
timepoint, SNI mice and sham mice displayed equivalent wheel running activity (Fig. 2B). These 
findings were obtained during the light cycle and are supported by our previous observations 
that SNI mice ran equivalent distances to uninjured mice when given wheel access for either 2 
or 12 hr per night, the time at which mice are most active.73 
 Similarly, we tested whether nerve injury suppressed social interaction with an 
unfamiliar age-, sex-, and strain-matched conspecific. We observed that social interaction 
scores were unchanged in SNI mice relative to sham mice on POD 8 or 14 (Fig. 2C-E).  
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Interestingly, previous studies show SNI-induced decreases in rodent social interaction at 
postoperative timepoints more acute (POD 5)64,94, but not long-term (POD 40)87, than those we 
tested. Taken together, our results demonstrate that despite ongoing mechanical 
hypersensitivity, neither voluntary wheel running nor social interaction were suppressed by 
nerve injury. 
 
SNI induced gait and motor deficits  
Using the Catwalk gait analysis system, we tested whether nerve injury altered gait. 
Significant changes in both static and dynamic gait parameters were observed after SNI from 
POD 11 to 39. Analysis of static gait parameters revealed that compared to sham-operated 
mice, ipsilateral hindpaw pressure of SNI mice was significantly decreased (Fig. 2F). However, 
no changes in contralateral hindpaw pressure were observed (Fig. 2G). As with other rodent 
sciatic nerve injury models68,93, SNI gave rise to cupping of the hindpaw, highlighted by a 
significant reduction in hindpaw maximum contact area compared to sham-operated mice (Fig. 
2H). Analysis of dynamic gait parameters demonstrated that the run speed of SNI mice was 
comparable to sham mice (Fig. 2I). However, SNI mice displayed a significantly shorter stance 
Figure 2. SNI produced gait alterations, but did not influence locomotion, social interaction, or 
anxiety-like behavior. (A) Spared nerve injury (SNI) caused a significant reduction in hindpaw 
mechanical withdrawal thresholds compared to sham operation on postoperative days (POD) 7-40 (n=10-
17/group). (B) SNI and sham mice exhibited equivalent wheel running activity at each testing timepoint 
between POD 5 and POD 41 (n=12-18/group). Representative heatmaps from the social interaction test 
of (C) sham and (D) SNI mice in the absence (top) and presence (bottom) of an unfamiliar conspecific. 
Presence within circles reflects time spent atop the pencil cups. Scale bar indicates total time spent in 
each arena location. (E) Social interaction scores were equivalent between sham and SNI mice on POD 
8/14 (n=15/group). (F, G) Catwalk gait analysis demonstrated a significant reduction in ipsilateral hindpaw 
pressure, but no change in contralateral hindpaw pressure of SNI mice relative to sham mice on POD 11 
through POD 39 (n=10-23/group). (H) SNI significantly decreased hindpaw contact area compared to 
sham surgery. (I) Catwalk run speed did not differ between SNI and sham mice. (J, K) SNI mice had a 
significantly shorter stance phase and significantly longer swing phase relative to sham mice on POD 11 
through POD 39. (L) SNI mice were impaired in the rotarod test, and had a significantly shorter latency to 
fall compared to sham mice across all trials on POD 8 (n=10-12/group). (M, N) SNI did not affect distance 
moved or time spent moving in the open field test on POD 14-17 (n=12-16). (O) SNI mice did not exhibit 
anxiety-like behavior in the open field test compared to sham mice on POD 14-17. Data are presented as 
mean ± SEM. Student’s t-Test, Holm-Sidak correction for multiple comparisons, when appropriate. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, as compared with sham mice. 
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phase (Fig. 2J), as well as significantly longer swing phase (Fig. 2K) relative to sham controls. 
Interestingly, in contrast to bilateral CFA, all static and dynamic gait deficits following SNI 
persisted as long as mechanical hypersensitivity, through at least POD 39. 
Multiple studies have demonstrated gait deficits following nerve injury in rodents.8,46,59,61 
However, whether these effects represent a pain-avoidance behavior or simply a motor deficit is 
uncertain.85 To address this, we tested gross motor coordination of nerve-injured mice using the 
accelerating rotarod test on POD 8. Indeed, SNI mice displayed a significant motor impairment 
across all test trials. SNI mice had a significantly shorter latency to fall off the rotarod than sham 
mice (Fig. 2L). Urban et al. also observed SNI-induced motor impairment in the rotarod test.87 
Thus, SNI-induced gait deficits may be the product of gross motor deficits.  
 
SNI did not induce changes in open field behavior  
 To determine whether nerve injury suppressed locomotor behavior or induced anxiety-
like behavior, we evaluated open field activity on POD 14-17. SNI mice did not differ from sham 
mice with respect to distance moved (Fig. 2M) or time spent moving (Fig. 2N) in the open field 
test. Our findings support those of existing studies demonstrating that gross locomotion of mice 
is unchanged after SNI.9,87,94 Lastly, percent time spent in the center zone of the open field was 
equivalent between SNI mice and sham mice (Fig. 2O), suggesting that at this timepoint, nerve-
injured mice were not in a general anxiety-like state, as supported by previous findings.87 
 
Summary of CFA- and SNI-induced changes in voluntary behavior and animal wellbeing  
 We demonstrated that inflammation and nerve injury differentially affect voluntary 
behaviors (Table 1). In addition to causing mechanical hypersensitivity, bilateral intraplantar 
injection of CFA transiently suppressed voluntary wheel running, decreased locomotor activity, 
and altered static and dynamic gait parameters. However, neither social interactions nor 
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anxiety-like behavior were affected by CFA (Fig. 1). Interestingly, all inflammation-induced 
changes in voluntary behaviors resolved by PID 5, whereas inflammation-induced mechanical 
hypersensitivity persisted through PID 9.  
 
 In contrast, despite robust and persistent mechanical hypersensitivity, SNI did not 
suppress voluntary wheel running, social interactions, or locomotor activity. Further, SNI did not 
induce general anxiety-like behavior in the open field. SNI did produce changes in both static 
and dynamic gait parameters that, like mechanical hypersensitivity, persisted the entire length of 
our study, through POD 39 (Fig. 2). However, it is possible that these gait alterations are in part 
the product of a general motor deficit, as suggested by impaired rotarod performance of SNI 
mice.  
In addition to evaluating voluntary behaviors following injury, we also monitored body 
weight as a measure of general animal health.6 CFA mice had body weights equivalent to saline 
mice through PID 14 (Fig. 3A). Likewise, body weights of SNI mice were equivalent to sham 
mice through postoperative week 6 (Fig. 3B). In summary, despite ongoing mechanical 
Table 1. Inflammation and nerve injury differentially affect voluntary behaviors while mice display 
mechanical hypersensitivity 
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hypersensitivity, inflammation and nerve injury do not 
negatively impact overall animal health, and have primarily 
short-lived effects on voluntary behaviors. 
 
CFA- and SNI-induced changes in voluntary behavior did 
not correlate with mechanical hypersensitivity  
When changes in voluntary behavior were 
observed after inflammation or nerve injury, we performed 
correlation analyses to test whether the degree of change 
in voluntary behavior correlated to the degree of change in 
the mechanical withdrawal threshold for a given animal. 
Following bilateral CFA, attenuated hindpaw mechanical 
withdrawal thresholds on PID 0 were not significantly 
correlated with decreased voluntary wheel running on PID 
1 (Fig. 4A, r(10)=-0.349, p=0.267), as has been reported 
previously in rats.24 It has been suggested that hindpaw 
pressure measured via the Catwalk gait analysis system 
provides an objective readout of mechanical 
hypersensitivity. For instance, in some cases, a correlation has been reported between 
mechanical hypersensitivity and decreased hindpaw pressure following inflammation or nerve 
injury in rodents.21,46,89 However, we found no correlation between CFA-induced mechanical 
hypersensitivity on PID 0 and reduced Catwalk hindpaw pressure on PID 1 (Fig. 4B, 
r(21)=0.248, p=0.255). Likewise, following SNI, attenuated hindpaw withdrawal thresholds on 
POD 7 did not correlate with decreased Catwalk hindpaw pressure measured on POD 11 (Fig. 
4C, r(17)=-0.0077, p=0.9750). Taken together, our results demonstrate that neither 
Figure 3. Neither CFA nor SNI 
affected mouse body weight. (A) 
Body weight of Complete Freund’s 
Adjuvant (CFA) mice was equivalent to 
saline mice from PID 0 through PID 14 
(n=13-42/group). (B) Body weights of 
spared nerve injury (SNI) and sham 
mice were equivalent between 
postoperative weeks 0 and 6 (n=23-
38/group). Data are presented as 
mean ± SEM. Student’s t-Test, Holm-
Sidak correction for multiple 
comparisons.  
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inflammation- nor nerve injury-induced changes in voluntary behavior correlate to mechanical 
hypersensitivity. Thus, while each endpoint requires mice to ambulate on the injured 
hindpaw(s), voluntary wheel running and hindpaw pressure are not simply alternative measures 
of mechanical hypersensitivity.  
 
SNI-induced mechanical hypersensitivity, but not reduced hindpaw pressure, was reversed by 
an analgesic  
 Lastly, we tested if the angiotensin II type 2 receptor antagonist PD123319 could reverse 
SNI-induced gait deficits to determine whether these were indeed pain-related changes. We 
were particularly interested in the effects of PD123319 on SNI-induced reductions in hindpaw 
pressure, which has been recommended as an objective measure of mechanical 
hypersensitivity.14,21,61,89 Administration of PD123319 (10 mg/kg, i.p.), but not saline, significantly 
increased mechanical withdrawal thresholds of SNI mice (Fig. 5A, two-way RM ANOVA, Sidak 
correction: F(2,42)=3.816, p=0.03 for drug group x test session interaction). This interaction was 
Figure 4. CFA- and SNI-induced changes in voluntary behavior did not correlate with mechanical 
hypersensitivity. (A) Following bilateral Complete Freund’s Adjuvant (CFA), reductions in hindpaw 
withdrawal thresholds on post injection day (PID) 0 did not correlate with decreased voluntary wheel 
running distances (n=12, r(10)= -0.349, p=0.267) or (B) reduced Catwalk hindpaw pressure (n=23, 
r(21)=0.248, p=0.255) measured on PID 1. (C) Attenuated hindpaw mechanical withdrawal thresholds of 
spared nerve injury (SNI) mice on postoperative day (POD) 7 did not correlate with reduced Catwalk 
hindpaw pressure on POD 11 (n=19, r(17)= -0.0077, p=0.9750). Each data point represents one individual 
mouse. Correlation analyses were performed to calculate the Pearson correlation coefficient (r).  
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driven by significantly increased 
mechanical withdrawal thresholds of SNI 
mice treated with PD123319 compared to 
those treated with saline on the day of 
drug administration (Post-hoc Student’s t-
Test: t=3.018, p=0.0110), and significantly 
increased mechanical withdrawal 
thresholds within the PD123319 group on 
the drug session compared to pre-drug 
and post-drug sessions (Post-hoc 
Student’s t-Tests: for pre-drug compared 
to drug, t=4.672, p<0.0001; for post-drug 
compared to drug, t=4.984, p<0.0001). In 
contrast, compared to saline, 
administration of PD123319 did not 
significantly alter SNI-induced decreases 
in Catwalk hindpaw pressure, and no 
differences were observed within the 
PD123319 group across testing sessions 
(Fig. 5B). SNI-induced changes in 
hindpaw contact area, stance phase, and 
swing phase were similarly unaffected by 
PD123319 (data not shown). Furthermore, 
compared to pre-drug and post-drug 
sessions, PD123319 did not alter 
Figure 5. The analgesic PD123319 reversed SNI-
induced mechanical hypersensitivity, but not SNI-
induced decreases in Catwalk hindpaw pressure. 
(A). Systemic administration (10 mg/kg, i.p.) of the 
angiotensin II type 2 receptor antagonist PD123319, but 
not saline, significantly increased mechanical withdrawal 
thresholds of spared nerve injury (SNI) mice on 
postoperative days (POD) 12-15 or 26-30. Data from 
these timepoints were pooled together. (n=11-12/group, 
two-way RM ANOVA, Sidak Correction: F(2,42)=3.816, 
p=0.03 for drug group x test session interaction). 
Mechanical withdrawal thresholds of SNI, PD123319 
were significantly greater than SNI, saline mice following 
drug administration (Post-hoc Student’s t-Test: t=3.018, 
p=0.0110). Within the SNI, PD123319 group, drug 
administration significantly increased mechanical 
withdrawal thresholds compared to pre-drug and post-
drug sessions. (Post-hoc Student’s t-Tests: for pre-drug 
compared to drug, t=4.672, ****p<0.0001; for post-drug 
compared to drug, t=4.984, ****p<0.0001). (B) 
Compared to pre-drug and post-drug sessions, or 
administration of saline, PD123319 did not change 
Catwalk hindpaw pressure of SNI mice on POD 9-12 
(n=5-8/group). Data are presented as mean ± SEM.  
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mechanical withdrawal thresholds or hindpaw pressure of the contralateral, uninjured hindpaw 
of SNI mice (data not shown). In summary, PD123319 significantly reversed SNI-induced 
mechanical hypersensitivity, but had no effect on SNI-induced reductions in Catwalk hindpaw 
pressure. Our findings contribute to the growing literature from both rats and mice 
demonstrating that nerve-injury induced gait deficits are not reversed by analgesics.46,59  
Although we also observed CFA-induced decreases in voluntary wheel running and 
Catwalk hindpaw pressure, we did not test whether these changes in voluntary behavior could 
be reversed by known analgesics. Cobos et al. have thoroughly demonstrated that non-steroidal 
anti-inflammatory drugs and morphine prevent inflammation-induced suppression of voluntary 
wheel running.12 While to our knowledge prevention or reversal of gait deficits resulting from 
intraplantar CFA have not yet been demonstrated, we observed a relatively small decrease in 
hindpaw pressure in CFA mice (8.6% decrease from baseline, Fig. 1G), which provides little 
dynamic range for reversal by an analgesic.  
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2.5 Discussion 
In response to the widely critiqued translational gap between preclinical and clinical 
measures of pain 2,10,13,37,43,45,65,72,85,88, we evaluated whether voluntary behaviors are interrupted 
in rodent models of persistent pain. Specifically, we tested for inflammation- and nerve injury-
induced changes in voluntary wheel running, locomotion, gait, social interaction, and general 
anxiety-like behavior. There is currently conflicting evidence regarding the relevance of these 
endpoints as pain-related behaviors. However, in order to establish a new, reliable rodent pain-
related behavior, it must be reversible by existing analgesics and validated by multiple 
independent investigators. In the present study, we demonstrate that inflammation and nerve 
injury minimally interfere with wheel running, locomotion, gait, social interaction, and anxiety-like 
behaviors in mice. Although significant nerve injury-induced gait deficits were observed, they 
were not reversed by the analgesic PD123319. Thus, we conclude that these voluntary 
behaviors are not reliable pain-related readouts across rodent injury models.  
 
CFA- and SNI-induced changes in physical activity are transient, if present  
We tested whether voluntary measures of physical activity and mobility – wheel running, 
open field locomotion, and gait – are impaired in mice following CFA or SNI. We found that 
bilateral CFA reduced each measure of physical activity and mobility for up to 3 days post 
injection, suggesting that CFA transiently suppresses global physical activity in mice. These 
findings are in close alignment with similar studies of CFA-induced decreases in voluntary wheel 
running.12,24,31,60 In contrast, unilateral SNI impaired gait (see below), but otherwise did not 
interfere with physical activity or mobility. Previous studies support our finding that open field 
locomotion is unaffected by nerve injury.9,46,87,92,94 However, our data demonstrating that nerve 
injury does not suppress wheel running raises questions.  
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A distinguishing feature of our wheel running paradigm is that mice were provided acute 
(2 hr), rather than homecage (24 hr) wheel access, which could have influenced our null 
observation. However, existing studies in which rodents were provided homecage wheel access 
provide conflicting evidence regarding voluntary wheel running as a pain-related behavioral 
endpoint following nerve injury. Pitzer et al. report that SNI attenuated homecage wheel running 
distances in mice, and differences between sham and SNI mice were only apparent during the 
dark cycle.61 However, Grace et al. observed no difference in homecage running distances 
between sham and CCI rats23, and our previous work similarly found no difference between 
running distances of naïve and SNI mice that were given acute access for 2 or 12 hr/night.73  
Another noteworthy feature of our nerve injury studies is that SNI was unilateral. We and 
others have found that bilateral CFA, but not unilateral CFA, suppresses voluntary wheel 
running12. These results suggest that rodents may be better able to adapt to unilateral hindpaw 
injury compared to bilateral injury. Whether the nerve injury model, injury laterality, testing time 
of day, or extent of wheel access prior to and/or following induction of pain underlie these 
discrepancies requires further investigation. Collectively, our present and previous data support 
that voluntary wheel running, and more broadly physical activity, is reliably suppressed for short 
a time post-injury by inflammation, but not by nerve injury.  
Whether gait alterations represent pain-related/avoidance behaviors across rodent injury 
models is unclear.8,14,46,57,59–61,69,87 We found that both CFA and SNI reduced hindpaw pressure 
of the affected limb(s). In addition, SNI altered dynamic gait parameters including stance and 
swing phase, while CFA did not. The use of bilateral CFA versus unilateral SNI may underlie the 
apparent differences between the effects of inflammation and nerve injury on dynamic gait 
parameters within our study. In fact, previous rodent gait analysis studies of both unilateral 
inflammatory and nerve injury pain models show significant changes in stance and swing 
phases.8,14,46,59–61  
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Interestingly, we found that compared to the duration of mechanical hypersensitivity, gait 
alterations following CFA were transient, whereas gait changes following SNI persisted equally 
as long as mechanical hypersensitivity. As the SNI model involves ligating both sensory and 
motor axons, we hypothesized that SNI-induced gait changes were due in part to a motor 
deficit, and our data suggest that this is the case. First, like others87, we found that SNI impaired 
gross motor coordination measured via the rotarod test. Similarly, our previous results show that 
SNI mice were impaired in the inverted screen test and had significantly atrophied 
gastrocnemius muscles73, further demonstrating the impact of SNI on motor axons. Second, 
although nerve injury-induced gait changes have been proposed to reflect pain-related 
behavior61, to our knowledge, only one previous study has evaluated the effect of analgesics on 
Catwalk gait deficits in mice.46 We show that SNI-induced gait changes were not reversed by 
the analgesic PD123319. Together, these findings indicate that nerve injury induced-changes in 
gait are not driven by pain; rather, they are likely the product of a motor deficit. In contrast, it is 
likely that pain underlies inflammation-induced changes in gait, which have been successfully 
reversed by analgesics.1,59,69 These observations emphasize that demonstrating reversal via 
known analgesics is a crucial step in establishing new pain-related behaviors.  
Clinically, it is not uncommon for analgesics to reverse hypersensitivity, yet fail to 
improve other aspects of chronic pain.19 Indeed, assays used in the present study likely 
generate differing nociceptive inputs: the von Frey test of mechanical hypersensitivity entails 
focal hindpaw mechanical stimulation, whereas voluntary behavior assays such as gait analysis 
or wheel running reflect nociceptive inputs integrated from the entire hindpaw. Thus, it is 
possible our observation that PD123319 reverses SNI-mechanical hypersensitivity, yet fails to 
reverse SNI-induced gait deficits, reflects differences in analgesic efficacy of PD123319 on 
differing nociceptive stimulus inputs. However, this possibility is contradicted by the finding that 
PD123319 successfully reverses SNI-induced changes in voluntary behavior in assays that 
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similarly vary in nociceptive inputs, including the warm/cool plate avoidance system as well as 
the mechanical avoidance assay.74  
 
Neither CFA nor SNI alter social interactions  
There is growing evidence from clinical and preclinical studies that chronic pain both 
influences and is influenced by social interactions.34,38,39,44,60,61,78 For instance, patients report 
that pain substantially interferes with social activities and relationships.30,53,90 Like humans, mice 
partake in complex social interactions.75,86 The social approach assay utilized here 
encompasses a combination of perhaps conflicting motivations including social investigation, 
play, offensive aggression, and/or perception of the stimulus mouse as a stressor.5 We found no 
effect of CFA or SNI on C57BL/6J social interactions on PID 2 or POD 8/14, respectively. 
Previous studies have similarly shown that social interactions are unchanged in mice following 
inflammation36,87, and reduced acutely (POD 5) after nerve injury, if at all.87,94 These data 
suggest that changes in social interaction do not reliably manifest in common mouse models of 
persistent pain. Notably, C57BL/6J mice display high sociability compared to other mouse 
strains5,71, which may mask the effects of injury on social behavior. Thus, the impact of 
inflammation and nerve injury on social interaction across strains requires further investigation.  
 
Neither CFA nor SNI induce anxiety-like behavior  
There is an increased prevalence of anxiety in chronic pain patients.25,30 To test whether 
persistent pain similarly induces anxiety-like behavior in mice, we utilized the open field test and 
found that neither CFA nor SNI elicited anxiety-like behavior during ongoing mechanical 
hypersensitivity. Previous studies using the open field test have also reported a lack of anxiety-
like behavior in mice up to 4 weeks after inflammation or nerve injury.36,87 However, anxiety-like 
behavior has been detected in rodents using the elevated plus maze after both inflammation 
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and nerve injury, and is reversed by anxiolytics and analgesics.17,36,50,56,62,70 Therefore, it is 
possible that CFA and SNI mice would have exhibited anxiety-like behavior if we had used 
additional measures of anxiety-like behavior.  
 
Hypersensitivity and suppressed voluntary behaviors represent different aspects of pain 
 We demonstrated that changes in mechanical withdrawal thresholds and voluntary 
behaviors represent distinct components of inflammation and nerve injury. We found no 
correlation between CFA- and/or SNI-induced mechanical hypersensitivity and decreased 
Catwalk hindpaw pressure or voluntary wheel running. Similarly, studies of other rodent 
voluntary behaviors such as burrowing and sleep cycle report no correlation with 
hypersensitivity.35,47 These results support the idea that changes in paw-withdrawal reflexes and 
voluntary behavior are driven by different pathophysiologies.45,87 For instance, compared to 
mechanical withdrawal reflexes, voluntary wheel running is a complex behavior that engages 
reward circuitry.4,54 In turn, disruption of this behavior by pain likely reflects a combination of 
somatosensory, affective, and motivational changes.  
 
Changes in voluntary behavior are not characteristic of persistent pain in mice  
Improving the translatability of basic research findings is a priority to the field. In turn, 
considerable efforts have been directed towards identifying measures of spontaneous pain in 
rodent models. While impairment of voluntary behaviors and quality of life measures have 
successfully been reversed by analgesics in rodent models of acute pain42,81,82, the present 
study and others demonstrate that these endpoints are less informative in common rodent 
models of persistent pain.46,87 In most cases, there are either no or only modest, short-lived 
changes in voluntary behavior, which limit the ability to study the time course of pain pathologies 
and the efficacy of novel analgesics. These observations raise two important possibilities. 
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Foremost, spontaneous pain may be either short-lived or well-masked in mice because as prey 
animals, it is evolutionarily disadvantageous for mice to display signs of injury or weakness. 
Second, while mice certainly display sensitization after injury, it is possible that mice do not 
experience pain as a complex sensory and emotional state as humans do. Both of these 
possibilities could represent a formidable challenge of using mice to model the negative impact 
of chronic pain on the quality of life of humans.  
Despite these obstacles, there are a variety of promising tools to bridge the translational 
gap between rodent and human pain research. For instance, operant and classical conditioning 
assays such as the mechanical conflict system and conditioned place preference/aversion 
possess predictive validity as measures of motivational aspects of pain.26,51 Further, agnostic 
approaches to analyzing rodent body language and behavioral phenotypes may reveal novel 
endpoints that access the presence of ongoing sensitization in rodents without 
anthropomorphizing.40,91 Thus, although we found minimal effects of inflammation and nerve 
injury on mouse physical activity, social interaction, or anxiety-like behavior, using operant 
assays or agonistic approaches in conjunction with traditional measures of nociceptive 
thresholds may aid in increasing the translation of preclinical findings.  
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Chapter 3 
 
Metabotropic glutamate receptor 2/3 (mGluR2/3) activation suppresses 
TRPV1 sensitization in mouse, but not human sensory neurons 
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3.1 Abstract 
The use of human tissue to validate putative analgesic targets identified in rodents is a 
promising strategy for improving the historically poor translational record of preclinical pain 
research. We recently demonstrated that in mouse and human sensory neurons, agonists for 
metabotropic glutamate receptors 2 and 3 (mGluR2/3) reduce membrane hyperexcitability 
produced by the inflammatory mediator prostaglandin E2 (PGE2). Previous rodent studies 
indicate that mGluR2/3 can also reduce peripheral sensitization by suppressing inflammation-
induced sensitization of TRPV1, but to date, whether this observation similarly translates to 
human sensory neurons has not been tested. Here, we demonstrate using calcium imaging that 
activation of mGluR2/3 with the agonist APDC suppresses PGE2-induced sensitization of 
TRPV1 in mouse, but not human sensory neurons. We also evaluate sensory neuron 
expression of the gene transcripts for mGluR2 (Grm2), mGluR3 (Grm3), and TRPV1 (Trpv1) 
using in situ hybridization. We show that the majority of Trpv1+ mouse and human sensory 
neurons express Grm2 and/or Grm3, and in both mouse and human, Grm2 was expressed in a 
greater percentage of sensory neurons than Grm3. Although our calcium imaging studies 
demonstrated a functional difference in the modulation of TRPV1 sensitization by mGlu2/3 
activation between mouse and human, there were no species differences in the gene transcript 
colocalization of mGluR2 or mGluR3 with TRPV1 that might explain this functional difference. 
Taken together with our previous work, these results suggest that activation of mGluR2/3 
suppresses some, but not all, aspects of human sensory neuron sensitization caused by PGE2. 
These differences have implications for potential future healthy human voluntary studies or 
clinical trials that seek to assess the analgesic efficacy of mGluR2/3 agonists or positive 
allosteric modulators.  
 
 
 73 
 
3.2 Introduction  
Species differences between rodents and humans have been proposed to contribute to 
the low success rate of analgesic drug development.6,43,67,68 In preclinical research, putative 
analgesics are oftentimes identified and exclusively evaluated in rodent tissues and/or pain 
models prior to entering clinical trials, in which such drugs seldom demonstrate efficacy.38,47,68 
Therefore, using primary human neurons to validate preclinical rodent findings is an appealing 
strategy to improve the translational success of basic pain research findings. With this goal in 
mind, we and others have established approaches to obtain and utilize human sensory neurons 
to better understand human nociceptor physiology.1,8,22,32,64,74  
The group II metabotropic glutamate receptors (mGluRs) have recently been identified 
as putative targets for pain relief in rodents.3,14,15,19,26,36,37,39,51,58,59,70–72 mGluR2 and mGluR3 are 
seven transmembrane domain Gi-protein coupled receptors that decrease cAMP formation, 
activate potassium channels, and inhibit voltage-gated calcium channels to reduce neuronal 
excitability and synaptic transmission 21,35. While group II mGluRs are expressed at each level of 
the pain neuraxis11–13,19,23,39,52,60,65, several lines of evidence suggest that activation of mGlu2 
and mGlu3 receptors in peripheral sensory neurons is sufficient for analgesia. For instance, in 
rodent inflammatory and neuropathic pain models, pharmacological activation of mGluR2/3 
expressed on peripheral primary afferents can attenuate pain-like behavior by suppressing 
sensory neuron sensitization in response to algogens and inflammatory mediators.3,14,15,23,26,70 
Conversely, pharmacological inhibition of peripheral mGluR2/3 can prolong pain-like behavior 
and increase sensory neuron activity, suggesting endogenous activation of mGluR2/3 is 
analgesic.15,71 Given the centrally mediated adverse effects of existing analgesics such as 
opioid addiction and abuse, peripheral analgesic targets are of particular interest.  
Our recent studies on cultured human dorsal root ganglia (DRG) neurons suggest 
peripheral mGlu2/3 receptors may be clinically relevant analgesic targets. We demonstrated 
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both anatomical and functional expression of group II mGluRs in human DRG.23 Importantly, as 
in mouse, mGluR2/3 activation blocked human nociceptor membrane hyperexcitability produced 
by the inflammatory mediator prostaglandin E2 (PGE2), indicating that a mechanism for 
peripheral analgesia may be conserved across species.23 Rodent studies suggest mGlu2/3 
receptors expressed on sensory neuron peripheral terminals can also reduce sensory neuron 
sensitization by suppressing sensitization of TRPV114,15,26,70, a nonselective cation channel that 
detects noxious stimuli and is critical for inflammation-induced peripheral sensitization.16,17,24,48 
The present study tested whether the same mechanism is conserved in human. We utilized 
sensory neurons obtained from organ donors without chronic pain to determine whether 
mGluR2/3 activation blocks inflammation-induced sensitization of TRPV1 in human neurons. 
We demonstrate that group II mGluR activation suppresses PGE2-induced sensitization of 
TRPV1 calcium responses in mouse, but not human sensory neurons. Interestingly, these 
functional differences were not explained by species differences in coexpression of the TRPV1 
gene transcript with mGlu2 or mGlu3 receptor gene transcripts.  
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3.3 Materials and Methods 
Animals  
All experiments were performed in compliance with protocols approved by the Animal 
Studies Committee of Washington University in St. Louis (Protocol Numbers 20150246 and 
20160097). Experiments were conducted on 5-8 week old C57BL/6J male and female mice 
(Jackson Lab, Bar Harbor, ME). Mice were housed in an animal facility with a 12-hour light-dark 
cycle and given food and water ad libitum.  
 
Donors  
Human tissue was obtained in compliance with procedures approved by Mid-America 
Transplant (St. Louis, MO), and the Human Research Protection Office at Washington 
University in St. Louis provided an International Review Board waiver. Human dorsal root 
ganglia (DRG) were obtained from organ donors with full legal consent for use of tissue for 
research. Only donors without a history of chronic pain were used in this study (Table 1).   
 
 
 
 
 
 
 
 
Mouse DRG cultures  
Each cell culture reagent vendor and catalog number has been listed previously.64 For 
each tissue preparation, two age- and sex-matched mice were sacrificed by live decapitation, 
 
 
 
 
 
 
 
 
 
 
 
 
 
y, year; FISH, fluorescent in situ hybridization  
Donor  Age, y Sex Race Cause of Death Tissue Uses  
1 21 Male White Stroke Ca2+ imaging 
2 55 Female White Stroke Ca2+ imaging, FISH 
3 22 Male Black Anoxia Ca2+ imaging 
4 44 Female White Stroke Ca2+ imaging 
5 12 Female White Anoxia Ca2+ imaging, FISH 
6 26 Male White Head Trauma Ca2+ imaging, FISH 
7 18 Female White Head Trauma Ca2+ imaging, FISH 
8 18 Male White Head Trauma Ca2+ imaging, FISH 
Table 1. Donor information and tissue 
uses 
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and cervical through lumbar DRG were removed and pooled together. DRG were incubated in 
papain (45 U) for 20 min at 37°C, 5% CO2. DRG were then rinsed and incubated in collagenase 
(1.5 mg/mL) for 20 min. Both enzyme solutions were made up in Ca2+- and Mg2+-free Hank’s 
buffered salt solution with 10 mM HEPES. DRG were manually triturated with fire-polished 
Pasteur pipettes to dissociate neurons, passed through a 40-µm filter, and plated onto poly-D-
lysine/collagen coated 12 mm glass coverslips. Neurons were maintained in culture for 2 days in 
Neurobasal A media supplemented with 100 U/mL penicillin/streptomycin, 2 mM GlutaMAX, 
B27, and 5% fetal bovine serum.  
 
Human DRG cultures 
Human DRG from the first through the fifth lumbar vertebra were extracted and cultured 
as described in detail previously.64 Briefly, following surgical extraction, fat and dura were 
trimmed away from the ganglia. DRG were minced and incubated in papain for 1 hr, rinsed, and 
incubated in collagenase for 1 hr. Both enzyme solutions were made up in an N-methyl-D-
glucamine artificial cerebrospinal fluid solution. DRG were manually triturated with fire-polished 
Pasteur pipettes to dissociate neurons, passed through a 100-µm filter, and plated onto poly-D-
lysine/collagen coated 12 mm glass coverslips. Neurons were maintained in culture for up to 9 
days in the media described above. Every 3 days, half of the culture media was replaced with 
fresh media to ensure neuronal health.  
 
Calcium imaging 
Calcium imaging was performed as described previously with modifications.63,64 Cultured 
neurons from mouse and human were incubated with 3 µg/mL of the ratiometric calcium 
indicator Fura-2 AM (Life Technologies, Carlsbad, CA) for 45 min. Neurons were then incubated 
in external solution for 15 min to allow for deesterification of Fura-2 AM. External solution 
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consisted of (in mM): 130 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 30 Glucose, and 10 HEPES. For 
recordings, coverslips were placed into a chamber and perfused with room temperature external 
solution. Cells were viewed under an inverted microscope (Olympus Optical, Tokyo, Japan) and 
fluorescent images were acquired every 2 s using a Hamamatsu ORCA camera (Hamamatsu, 
Bridgewater, NJ). SimplePCI Software (HCImage, Hamamatsu Corporation, Sewickley, PA) was 
used to identify regions of interest surrounding Fura-2 AM loaded neurons a priori and to record 
fluorescence emission at alternating excitation wavelengths of 357 and 380 nm. 
 The experimental protocol entailed a 2 min baseline in external solution followed by a 20 
s bath application of 100 nM capsaicin (Sigma, St. Louis, MO), a 3 min wash of external 
solution, then a treatment condition entailing application of either 1) 7 min of vehicle (external 
solution), 6 min of 1 µM prostaglandin E2 (PGE2, Tocris, Minneapolis, MN), or 1 min of 10 µM 
(2R, 4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC, Tocris) alone followed by 6 min of 10 µM 
APDC plus 1 µM PGE2. Immediately after treatment, a second pulse of 100 nM capsaicin was 
bath applied, neurons were washed for 6 minutes with external solution, and a 10 s pulse of 50 
mM KCl was applied to test for cell viability. At least 2 treatment conditions were tested for a 
given mouse and donor tissue preparation. All drugs were diluted in external solution. Stock 
solutions of 2.8 mM PGE2 and 100 mM APDC were made up in DMSO and water, respectively. 
Peak calcium responses were calculated by dividing the absolute increase in Fura-2 AM signal 
following stimulus application by the proceeding 30 s baseline Fura-2 AM signal. The response 
threshold to capsaicin was defined as an increase ≥ 10% from baseline signal. Cells that did not 
respond to high KCl were excluded from calcium imaging analysis. 
 
Fluorescent in situ hybridization (RNAscope) 
At the conclusion of mouse and human calcium imaging experiments, neurons were 
fixed on ice with 4% paraformaldehyde/4% sucrose for 15 min and washed with phosphate 
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buffered saline (PBS). Fluorescent in situ hybridization studies were performed according to the 
protocol for cultured adherent cells using the RNAscope Multiplex Fluorescent Assay (Advanced 
Cell Diagnostics, Newark, CA) with minor modifications. Following dehydration and rehydration 
of cells in ethanol, glass coverslips were mounted onto glass slides using ethyl cyanoacrylate. 
Neurons were treated with protease III diluted 1:10 (mouse) or 1:5-7.5 (human) at room 
temperature for 10 min. Species-specific target probes for Trpv1, Grm2, and Grm3 (Table 2) 
were combined, applied to neurons, and allowed to hybridize for 2 hr at 40°C in a humidified 
oven. A series of incubations were then performed to amplify hybridized probe signal and label 
target probes with the assigned fluorescence detection channel (C1-C3). Coverslips were 
counterstained with DAPI using ProLong Gold Antifade Mountant (Invitrogen, Waltham, MA). 
Neurons were imaged at 40X using a Leica SPE confocal microscope. Fields of interest were 
identified in the DAPI channel. Fiji (Image J, NIH) software was used to calculate neuron 
diameter and manually quantify single RNA molecule signals. In the RNAscope assay, each 
punctate dot represents a single target RNA molecule. However, to reduce the likelihood of 
false positives, mouse and human neurons were defined as positive for a given RNA target if 
they had ≥ 4 puncta or ≥ 2 puncta, respectively, based on the range in neuron puncta density 
observed for each species.  
 
 
 
 
 
 
Figure 2. RNAscope probes used for fluorescent in situ hybridization 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Mm, mus musculus; Hs, homo sapiens; C2, channel 2; C3, channel 3 
Target Catalog Number 
Mm-Trpv1 313331 
Mm-Grm2-C3 317831-C3  
Mm-Grm3-C2 317821-C2 
Positive Control Probe-Mm 320881 
Hs-TRPV1 415381 
Hs-GRM2-C3 589771-C3 
Hs GRM3-C2 500181-C2 
Positive Control Probe-Hs 320861 
Negative Control Probe 320871 
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Statistical analyses 
The experimenter was blind to treatment condition and gene of interest throughout 
analysis of calcium imaging and in situ hybridization data, respectively. Microsoft Excel, 
GraphPad Prism (La Jolla, CA), R, and the R package Ime4 were used for data organization 
and statistical analyses.7,61 Calcium imaging data were analyzed using 1) unpaired t-tests and 
Bonferroni correction for multiple comparisons and 2) linear mixed-effects model analyses. 
Linear mixed-effects model analyses controlled for donor as a random-effect and the sex and 
age of donors as fixed-effects. As the primary objective of the present study was to make 
species comparisons, we were not sufficiently powered to evaluate the effects of mouse age or 
sex on calcium imaging outcomes. Species comparisons of the percentage of capsaicin-
responsive neurons and gene transcript expression were made using chi-square tests and 
Bonferroni correction for multiple comparisons, when appropriate. When describing and 
discussing species differences in gene transcript expression, we default to mouse mRNA 
nomenclature.  
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3.4 Results 
mGluR2/3 suppress PGE2-induced TRPV1 sensitization in mouse, but not human sensory 
neurons  
 TRPV1 is sensitized by the cAMP/PKA pathway, which is stimulated by inflammatory 
mediators such as PGE2.10,41,44,46,53 In contrast, group II mGlu receptor activation inhibits 
adenylyl cyclase and subsequent cAMP production.21,35 To determine whether mGluR2/3 
activation blocks TRPV1 sensitization, we quantified capsaicin-induced calcium responses of 
mouse and human sensory neurons. Two 20 s pulses of 100 nM capsaicin were bath applied to 
DRG neurons and the degree of TRPV1 sensitization was defined as the response ratio of the 
peak of the second capsaicin response divided by the peak of the first capsaicin response. 
Under vehicle conditions, TRPV1 desensitization is observed in both mouse and human DRG 
neurons in the form of reduced calcium responses to subsequent capsaicin pulses (Fig. 1A, B). 
In mouse sensory neurons, bath application of PGE2 between capsaicin pulses significantly 
increased the capsaicin response ratio compared to vehicle (Fig. 1A, C). Coapplication of the 
selective group II mGluR agonist APDC with PGE2 significantly reduced the response ratio 
compared to PGE2 alone (Fig. 1A, C). These findings confirm our previously published work in 
cultured sensory neurons obtained from CD-1 mice in which we also demonstrated that 
suppression of PGE2-induced TRPV1 sensitization by APDC is blocked by the group II mGluR 
antagonist LY341495, and thus is attributable to mGlu2/3 receptor activation.70  
In human sensory neurons, we found that while application of PGE2 between capsaicin 
pulses significantly increased the capsaicin response ratio compared to vehicle, the response 
ratio following coapplication of APDC with PGE2 did not significantly differ from application of 
PGE2 alone (Fig. 1B, D). Unlike rodents used in preclinical studies, human organ donors display 
wide demographic and genetic diversity. To determine whether a given organ donor was driving  
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Figure 1. mGlu2/3 receptor activation blocked PGE2-induced TRPV1 sensitization in mouse, but 
not human sensory neurons. Representative traces of 100 nM capsaicin-induced calcium responses 
in mouse (A) and human (B) dorsal root ganglia (DRG) neurons in response to vehicle (left), 1 µM 
PGE2 (middle), or 1 µM PGE2 + 10 µM APDC (right). Experiments concluded with a pulse of 50 mM 
KCl to determine cell viability. The degree of TRPV1 sensitization is expressed as a response ratio 
calculated by dividing the peak amplitude of Cap 2 by the peak amplitude of Cap 1 (A, dashed lines). 
(C) In mouse DRG neurons, PGE2 significantly increased the capsaicin response ratio compared to 
vehicle (****p<0.0001; n=143-150 neurons, N=4 preps/condition). Coapplication of APDC with PGE2 
blocked this effect, and significantly reduced the response ratio compared to PGE2 alone (**p=0.0081; 
n=89-150 neurons, N=3-4 preps/condition). (D) PGE2 also significantly increased the capsaicin 
response ratio of human DRG neurons compared to vehicle (****p<0.0001; n=59-71 neurons, N=5-6 
donors/condition); whereas coapplication of APDC did not suppress PGE2-induced increases in the 
capsaicin response ratio (p=1, n=59-64 neurons, N=6 donors/condition), which remained significantly 
greater than vehicle (**p=0.0053, n=64-71 neurons, N=5-6 donors/condition). Capsaicin response 
ratios were compared using unpaired t-tests and a Bonferroni correction for multiple comparisons. (E) 
Compared to mouse, a greater percentage of human DRG neurons responded to 100 nM capsaicin 
(chi square test, χ2=27.27, ****p<0.0001, mouse: 576/2552 neurons, N=4 preps, human: 227/705 
neurons, N=8 donors). (F) Linear mixed-effect model (LMM) regression correction for impact of 
individual donor, as well as donor age and sex, did not alter human capsaicin response ratio analysis 
statistical outcomes compared with t-tests alone. Data are presented as mean ± SEM. 
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our finding that mGluR2/3 activation fails to suppress PGE2-induced TRPV1 sensitization in 
human DRG neurons, we performed a linear mixed-effect model (LMM) regression to correct for 
donor variability. As the effect of age and sex on human sensory neuron physiology is of broad 
interest to pain researchers, these parameters were included as covariates in our LMM 
regression. Interestingly, we found that correcting for impact of individual donor, as well as 
donor age and sex, did not alter our calcium imaging outcome (Fig. 1F). Taken together, these 
results demonstrate that mGluR2/3 activation suppresses PGE2-induced TRPV1 sensitization in 
mouse, but not human sensory neurons.  
 We were also interested in whether the same percentage of mouse and human sensory 
neurons respond to capsaicin. Of the total number of sensory neurons evaluated in calcium 
imaging studies, 22.6% of mouse sensory neurons versus 32.2% of human sensory neurons 
responded to 100 nM capsaicin, indicating that human sensory neurons are modestly more 
capsaicin-responsive (Fig. 1E). These results are consistent with our initial observations that 
human sensory neurons exhibit greater chemosensitivity to algogens and pruritogens compared 
to rodents.22 In the present study, we chose to use 100 nM capsaicin to test for modulation of 
TRPV1 desensitization. Previous studies using higher concentrations of capsaicin (200 nM to 1 
uM) indicate that capsaicin elicits calcium responses in a greater proportion of mouse DRG and 
trigeminal neurons, ranging from 30 to 70%.5,24,27,45,55,63 
 
Mouse and human sensory neurons share similar Trpv1, Grm2, and Grm3 expression and 
coexpression profiles  
We hypothesized that the observed species differences in mGluR2/3 functional 
modulation of TRPV1 could be due to reduced coexpression between TRPV1 and mGlu2 and/or 
mGlu3 receptors in human versus mouse sensory neurons. We previously demonstrated 
mGluR2-immunoreactivity in human sensory neurons.23 However, due to the lack of highly 
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selective mGluR3 antibodies suitable for immunohistochemistry31, we assessed expression of 
TRPV1, mGluR2, and mGluR3 mRNA transcripts (referred to as Trpv1, Grm2, and Grm3, 
respectively) in dissociated sensory neurons using RNAscope fluorescent in situ hybridization 
(FISH). The mouse DRG neurons evaluated in FISH studies ranged from 10.0 to 35.5 µm in 
diameter, with a mean diameter of 17.7 ± 0.2 µm for the total population, and 20.3 ± 0.4 µm for 
Trpv1+ neurons (Fig. 2A). In comparison, human DRG neurons ranged from 10.0 to 56.3 µm in 
diameter, with a mean diameter of 31.9 ± 0.5 µm for the total population, and 33.9 ± 0.9 µm for 
TRPV1+ neurons (Fig. 2B). The mean diameter of the total human DRG neuron population was 
significantly larger than that of mouse (Fig. 2C). Our findings closely resemble the size 
distribution of mouse DRG neurons reported previously.4,25,50 Previous human studies show that 
the average sensory neuron diameter in unfixed tissues is between approximately 40-60 µm 
1,22,33,69,73, further highlighting the species difference in sensory neuron size. 
With respect to mRNA expression, of the total population of mouse DRG neurons, 
37.2% of neurons were positive for the Trpv1 gene transcript, 61.5% were positive for Grm2, 
and 30.9% were positive for Grm3 (Fig. 2D). Similar transcript expression was observed in 
human sensory neurons, with 32.2% of all neurons positive for TRPV1, 52.7% positive for 
GRM2, and 29.5% positive for GRM3 (Fig. 2E). Notably, a significantly greater percentage of 
total DRG neurons expressed Grm2 compared to Grm3 in both mouse (chi square, χ2 =74.56, 
p<0.0001) and human (chi square, χ2 =28.83, p<0.0001). While there was a trend towards an 
increased percentage of Grm2+ neurons in mouse compared to human DRG (chi square, 
Bonferroni correction, χ2 =2.229, p=0.077), there were no significant species differences in the 
expression of the transcripts of interest. We were also interested in whether human donors 
displayed differences in the percentage GRM2+, GRM3+, or TRPV1+ neurons, however 5 
donors was not sufficient to perform these analyses on FISH data.  
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Analysis of transcript coexpression showed that the majority of Trpv1+ mouse DRG 
neurons coexpressed Grm2, Grm3, or both. To elaborate, 33.3% of Trpv1+ neurons 
coexpressed Grm2, 7.5% coexpressed Grm3, and 44.2% coexpressed both Grm2 and Grm3 
(Fig. 2F). Of TRPV1+ human DRG neurons, 41.0% coexpressed GRM2, 8.4% coexpressed 
GRM3, and 32.5% coexpressed both GRM2 and GRM3 (Fig. 2G). No significant species 
differences were observed in the coexpression of Trpv1 with Grm2 and/or Grm3 gene 
Figure 2. Expression of Trpv1, Grm2, and Grm3 mRNA transcripts in dissociated mouse and 
human DRG neurons. (A) Size distribution of total and Trpv1+ mouse DRG neuron populations; 
mean diameter of total neurons: 17.7 ± 0.2 µm (n=395 neurons, N=4 preps), mean diameter of Trvp1+ 
neurons: 20.3 ± 0.4 µm (n=147 neurons). (B) Size distribution of total and TRPV1+ human DRG neuron 
populations; mean diameter of total neurons: 31.9 ± 0.5 µm (n=258 neurons, N=5 donors), mean 
diameter of TRPV1+ neurons: 33.9 ± 0.9 µm (n=83 neurons). Data are reported as mean ± SEM (C) 
The mean diameter of total human DRG neurons was significantly larger than total mouse DRG 
neurons (unpaired t-test, ****p<0.0001). Data are presented as mean ± SD. Percentage of total (D) 
mouse and (E) human DRG neurons that expressed Trpv1, Grm2, and Grm3, as well as the 
percentage of neurons that coexpressed one mRNA transcript with another. Pie charts showing the 
percentage of Trpv1+ (F) mouse and (G) human DRG neurons that coexpressed Grm2, Grm3, or 
both transcripts. No significant differences in total or Trpv1+ subpopulations were observed 
between species.  
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transcripts. Thus, these findings suggest that the absence of mGluR2/3-induced suppression of 
TRPV1 sensitization in human DRG neurons cannot be explained by reduced coexpression of 
TRPV1 with group II mGluRs at the gene transcript level.  
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3.5 Discussion 
Peripheral targets for pain relief are greatly desired given the centrally mediated side 
effects including addiction and misuse of current frontline analgesics such as opioids. In both 
mouse and human, activation of group II mGluRs blocks sensory neuron membrane 
hyperexcitability elicited by the inflammatory mediator PGE2.23 In the present study, we 
demonstrate that suppression of inflammation-induced TRPV1 sensitization represents an 
additional mechanism by which mGluR2/3 reduce peripheral sensitization in mouse, but not 
human sensory neurons. We further show equivalent colocalization of Trpv1 with Grm2 and 
Grm3 mRNA transcripts in mouse and human DRG neurons, suggesting that disparities in 
coexpression do not explain species differences in the functional modulation of TRPV1 by group 
II mGluRs. These findings indicate that while mGluR2/3 activation decreases sensory neuron 
sensitization in both mouse and human, mechanisms of peripheral analgesia are not fully 
conserved across species.  
 
mGluR2/3 functional differences in mouse and human sensory neurons  
 That the mGlu2/3 receptor agonist APDC did not suppress PGE2-induced TRPV1 
sensitization in human DRG neurons was a surprising observation. Foremost, cDNA and amino 
acid sequences of human and rodent mGluR2 and mGluR3 display at least 90% 
homology.29,35,42 In turn, APDC exhibits comparable potency at rodent and human group II 
mGluRs with respect to inhibition of stimulated cAMP responses.57 Our recent finding that 
APDC decreases excitability and increases action potential threshold in PGE2-treated sensory 
neurons of both species further suggests mGluR2/3 functional homology in mouse and human 
sensory neurons.23 Existing behavioral and in vitro rodent studies strongly suggest that inhibition 
of cAMP-dependent TRPV1 sensitization is another mechanism by which mGluR2/3 can block 
sensory neuron sensitization.14,15,26,70 Here, we substantiate these findings by demonstrating 
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that APDC blocks PGE2-induced TRPV1 sensitization in C57BL/6J mice. However, this 
observation did not translate in human sensory neurons despite the apparent similarities of 
mGluR2/3 function between species.  
There are multiple potential explanations for the lack of translation of mGluR2/3 
functional modulation of TRPV1 from mouse to human. For example, in addition to PKA, PGE2-
induced intracellular signaling cascades can activate other kinases known to sensitize TRPV1, 
including PKC and c-Src kinase.34,48,49,66 Thus, while we observed PGE2-induced sensitization of 
capsaicin responses in both mouse and human sensory neurons, it is possible that in contrast to 
mouse, PGE2-induced TRPV1 sensitization in human occurs via a predominantly PKA-
independent pathway that is not influenced by mGlu2/3 receptor activation. Further, there is 
evidence that postsynaptic group II mGluRs can also activate PKC in rodent hippocampal and 
cortical neurons.56,62 It is therefore possible that mGluR2/3 may activate intracellular signaling 
messengers such as PKC that sensitize TRPV1 to different extents in mouse and human 
sensory neurons. Further investigation of the intracellular mechanisms that 1) underlie PGE2-
induced sensitization and 2) are initiated by mGluR2/3 in human sensory neurons is therefore 
needed.        
Another important consideration is that while we observed equivalent coexpression of 
Grm2 and Grm3 gene transcripts in Trpv1+ mouse and human DRG neurons, whether 
equivalent coexpression of TRPV1 and mGluR2/3 also extends to the protein level remains 
unclear. For instance, it is possible that species differences exist in the regulation of translation, 
post-translational modifications, and subcellular compartmentalization of TRPV1 and mGlu2/3 
receptors. TRPV1-immunoreactivty has been demonstrated in human DRG neurons, peripheral 
nerves, and intraepidermal nerve fibers.1,2,28,33,40 However, until selective mGluR2 and mGluR3 
antibodies suitable for immunohistochemistry are generated, our ability to evaluate the 
coexpression and subcellular localization of group II mGluRs with TRPV1 remains limited. 
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Importantly, although mGlu2/3 receptor activation does not modulate sensitization of TRPV1 in 
human, the expression of GRM2 and/or GRM3 in the majority of small-diameter (< 50 µm) 
TRPV1+ human DRG neurons suggests that these receptors are well positioned to modulate 
nociceptor activity by alternative mechanisms. Thus, mGluR2/3 remain putative human 
peripheral analgesic targets.   
 
Sensory neuron expression of Grm2, Grm3, and Trpv1  
Existing immunohistochemical analyses of rodent DRG neurons demonstrate high 
colocalization of group II mGlu receptors with TRPV1, with 93% of TRPV1-positive neurons 
expressing mGluR2/3 and effectively all mGluR2/3-positive neurons expressing TRPV1.14 Here 
we demonstrate that the majority (≥ 81%) of Trpv1+ mouse and human sensory neurons also 
express Grm2 and Grm3 gene transcripts. In contrast, we found that in both mouse and human, 
only a subset (45-62%) of either Grm2+ or Grm3+ neurons also expressed the Trpv1 transcript. 
Importantly, prior immunohistochemistry studies using nonselective mGluR2/3 antibodies and 
RNA-seq analysis of homogenized DRG precluded analyses of which group II mGlu receptor is 
predominantly expressed in sensory neurons and to what extent mGluR2 and mGluR3 are 
coexpressed within the same neurons. We show for the first time that Grm2 is more highly 
expressed than Grm3 in mouse and human sensory neurons. Further, while Grm2 and Grm3 
are coexpressed in a subset (38-77%) of mouse and human sensory neurons, the transcripts 
are also expressed individually. These findings suggest that mGluR2 may play a larger role in 
modulating nociceptor excitability than mGluR3. Indeed, our previous behavioral studies 
demonstrate that the analgesic efficacy of group II mGlu receptor agonists persists in mGluR3-/-, 
but not mGluR2-/- mice, suggesting a greater role for mGluR2 than mGluR3 in pain regulation.72 
As repeated dosing with group II mGlu receptor agonists causes analgesic tolerance in 
rodents20,37, alternative strategies to reinforce endogenous activation of mGluR2 may be 
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required to effectively target group II mGlu receptors for clinical pain relief. Our results suggest 
that recently developed mGluR2-specific positive allosteric modulators may be promising agents 
for blockade of peripheral sensitization.3,30  
   
Distinctions between human and rodent sensory neurons  
In addition to differences in mGlu2/3 receptor function, we demonstrate that human 
sensory neurons possess distinct fundamental properties including increased diameter and an 
increased percentage of capsaicin-responsive neurons compared to mouse. Using calcium 
imaging, we found that 33.2% of human DRG neurons responded to 100 nM capsaicin. 
However, it is possible that a larger proportion of human sensory neurons expresses TRPV1 
and/or responds to capsaicin. For instance, previous immunohistochemical analysis of human 
DRG showed that roughly 55% of all DRG neurons were TRPV1-immunoreactive 1. Further, in 
calcium imaging experiments, ~60% of ganglionectomized DRG neurons removed due to 
chronic intractable pain responded to 100 nM capsaicin.8,9 These findings suggest that an even 
greater species difference in capsaicin-responsive neurons may exist between mice and 
humans than we report here. Of course, variability in experimental conditions or donor 
demographics, genetic diversity, and pain-related health conditions, could underlie differences 
in TRPV1 expression across human studies. For this reason, developing an extensive donor 
tissue bank to investigate DRG neuron gene and protein expression as well as to further 
characterize sensory neuron subpopulations will allow for more complete comparisons between 
species, and perhaps more interestingly, among donor subpopulations.  
Nevertheless, while only a small number of comparative studies of rodent and human 
sensory neurons have been conducted, it is becoming increasingly clear that species 
differences exist in gene expression, ion channel properties, and action potential firing 
patterns.18,32,54,73,74 Therefore, human sensory neurons represent a vital tool for improving our 
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understanding of human nociceptor physiology under both normal and pathological conditions. 
Further, using human sensory neurons to assess the validity of putative analgesic targets 
identified in rodents may lead to increased translational success of preclinical findings.  
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4.1 Abstract  
 
Both clinical and animal studies suggest that exercise may be an effective way to 
manage inflammatory and neuropathic pain conditions. However, existing animal studies 
commonly use forced exercise paradigms that incorporate varying degrees of stress, which 
itself can elicit analgesia, and thus may complicate the interpretation of the effects of exercise 
on pain. We investigated the analgesic potential of voluntary wheel running in the formalin 
model of acute inflammatory pain and the spared nerve injury model of neuropathic pain in 
mice. In uninjured, adult C57BL/6J mice, 1 to 4 weeks of exercise training did not alter 
nociceptive thresholds, lumbar dorsal root ganglia neuronal excitability, or hindpaw 
intraepidermal innervation. Further, exercise training failed to attenuate formalin-induced 
spontaneous pain. Lastly, 2 weeks of exercise training was ineffective in reversing spared nerve 
injury-induced mechanical hypersensitivity or in improving muscle wasting or hindpaw 
denervation. These findings indicate that in contrast to rodent forced exercise paradigms, short 
durations of voluntary wheel running do not improve pain-like symptoms in mouse models of 
acute inflammation and peripheral nerve injury.  
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4.2 Introduction 
Chronic pain is a debilitating condition that affects over 100 million Americans and has 
an annual cost of $635 billion in the form of health care expenses and productivity 
loss.34,45Clinical studies suggest aerobic exercise is an effective, non-invasive approach to 
managing ongoing inflammatory and neuropathic pain conditions, as well as musculoskeletal 
disorders.22,23,27,43,71 Similarly, exercise improves pain-like symptoms in rodent inflammatory and 
neuropathic pain models.1,5,8,18,20,21,29,37,50,63,64,66,67  
The effect of exercise on pain has been primarily evaluated using forced exercise 
paradigms. For example, recent studies have demonstrated that forced treadmill running 
following peripheral nerve injury reverses nerve injury-induced thermal and mechanical 
hypersensitivity in rats and mice.8,20,21,49,67 Extended swimming has also been shown to both 
attenuate the development of and reverse nerve injury-induced thermal and mechanical 
hypersensitivity in rodents, as well as formalin-induced spontaneous pain in rats.1,50,64 As 
acknowledged in these studies and others, forced exercise may elicit both acute and chronic 
stress responses that in turn can produce analgesia.14,16,52,56–58 Although most forced exercise 
studies have evaluated nociceptive thresholds after exercise-induced acute stress responses 
have resolved, prolonged forced exercise gives rise to chronic stress responses in some 
cases.52,56,57 Voluntary exercise may also elicit a stress response58; however, numerous studies 
demonstrate anxiolytic effects of prolonged voluntary wheel running in cases of mild to 
moderate stress.7,31,32,61,62 One way to minimize potential complications of stress dependent 
effects on pain is to use voluntary exercise paradigms.  
Voluntary wheel running has been shown to be effective in delaying decreases in muscle 
withdrawal thresholds and increased paw withdrawal frequency in mouse models of chronic 
muscle pain.66 Similarly, in a high-fat model of prediabetic neuropathy, voluntary wheel running 
reverses mechanical and visceral hypersensitivity.37 While these studies support that voluntary 
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wheel running improves pain-like behavior in rodents, reports utilizing voluntary exercise 
paradigms in injured and uninjured pain states are limited.  
To investigate whether repeated voluntary exercise sessions alter basal nociception in 
rodents, we determined whether voluntary wheel running changes nociceptive thresholds, 
sensory neuron excitability, or skin innervation in the absence of injury. We also investigated if 
voluntary exercise training alters acute inflammatory pain responses as well as the 
hypersensitivity, muscle wasting, or skin denervation induced by the spared nerve injury (SNI) 
model of neuropathic pain. We report that voluntary wheel running did not alter nociceptive 
thresholds in uninjured mice, and was ineffective in attenuating acute inflammatory or nerve-
injury induced pain.  
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4.3 Materials and Methods  
Ethics Statement 
The entire study was carried out in accordance to the guidelines of the Washington 
University in St. Louis Department of Comparative Medicine (DCM). The protocol was approved 
by the Animal Studies Committee of DCM (Protocol Number: 20130147).  
 
Animals 
Adult C57BL/6J male mice bred in house or obtained from Jackson Labs were housed 
and cared for in compliance with the Animal Studies Committee of Washington University in St. 
Louis. Mice were housed on a 12/12 hour (hr) light/dark cycle and had ad libitum access to food 
and water while in their home cages. Behavioral experiments were initiated on 7-10 week old 
mice. Over the course of testing, injury (if applicable), and exercise training, mice reached a 
maximum age of 14 weeks. At the conclusion of behavioral testing, mice were sacrificed using a 
rodent ketamine euthanasia cocktail.  
 
Exercise paradigm 
During exercise training, mice were placed into individual cages with low-profile wireless 
running wheels (Med Associates Inc.) for either 2 hr (6-8 PM) or 12 hr (7 PM-7 AM) a night, 5-6 
nights a week. A sixth night of training was required to maintain exercise states throughout 
behavioral testing. Distance ran was monitored using software from Med Associates Inc. Control 
animals were placed into individual cages with a locked running wheel. During 2 hr training 
sessions, white noise was used to mask external noises.  Animals trained overnight were 
provided food pellets and Hydrogels (ClearH2O) to prevent weight loss. Home cage access to 
running wheels – either unlocked or locked – was not used in our studies to minimize stress 
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associated with the chronic social isolation of single housing.40 When not exercising, animals 
were group housed in their home cages. 
 Exercise training was completed prior to the induction of acute inflammatory pain, which 
took place the afternoon following the last exercise bout. Specifically, intraplantar formalin was 
administered 16 hr after completion of 2 hr/night exercise sessions or 4-6 hr after completion of 
12 hr/night exercise sessions. In nerve-injury studies, exercise training began 8-10 days after 
surgery.  
 
Behavioral studies 
All behavioral assays were completed between 8 AM and 5 PM. Briefly, for the 
Hargreaves, von Frey, and cold plantar assays, mice were acclimated in plexiglass boxes to the 
testing platform and white noise for at least 2 hr prior to testing until exploratory behavior 
ceased. For the hot plate and inverted screen tests, mice were acclimated to the testing room in 
their home cage with white noise for at least 1 hr prior to testing. For all behavioral studies, the 
experimenter was blinded to training groups.  
 
Cold plantar assay 
Cold sensitivity was measured as previously described.12,13 Mice were acclimated to 
either a 3/8’’ or 1/4” glass plate and a cold probe was made by packing finely crushed dry ice 
into a modified syringe 1 cm in diameter. The cold probe was applied to the glass beneath the 
plantar surface of the hindpaw and the time to paw withdrawal was recorded. 5 trials were 
conducted on each hindpaw, with 7 minutes (min) between trials on opposite paws, and 15 min 
between trials on the same paw. A cut off latency of 20 seconds (sec) was used to prevent 
tissue damage. Withdrawal latencies were determined by averaging right and left paw 
responses. 
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Hargreaves 
Animals were acclimated on a glass plate held at 30°C (Model 390 Series 8, IITC Life 
Science Inc.). A radiant heat source was applied to the hindpaw and latency to paw withdrawal 
was recorded.39 5 trials were conducted on each paw, with at least 5 min between testing the 
opposite paw and at least 10 min between testing the same paw. To avoid tissue damage, a cut 
off latency of 20 sec was set. Values from both paws were averaged to determine withdrawal 
latency.  
 
Hot plate 
Prior to testing day, animals were individually acclimated to the hot plate chamber 
(Model PE34 Series 8, IITC Life Science Inc.) for 15 min. On the day of testing, one 
experimental trial was conducted in which each animal was placed onto a 55°C plate and the 
latency to response was recorded. “Response” was defined as the first act directed towards the 
hindpaw, which was primarily licking or shaking, or escape behavior such as jumping. A cut off 
latency of 20 sec was used to prevent tissue damage.  
 
von Frey  
Mice were acclimated on an elevated mesh grid and mechanical sensitivity was 
determined by applying von Frey filaments to the plantar hindpaw according to the up-down 
method as described previously.17 Three trials were conducted on each paw with at least 5 min 
between trials on opposite paws, and 10 min between trials on the same paw. Mechanical paw 
withdrawal thresholds of uninjured animals were obtained by averaging the 3 trials performed on 
both paws. Nerve-injured animals were tested on the lateral aspect of the hindpaw at both 
baseline and post-injury time points, and the average ipsilateral withdrawal thresholds were 
calculated.25 
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Formalin test  
For acute inflammatory pain, mice were acclimated in plexiglass boxes on a glass 
platform for 1 hr with white noise.  Mice were briefly removed from the platform and 10 µL of 2% 
formalin was injected subcutaneously into the hindpaw.  Mice were video recorded for 1 hr after 
formalin injection and time spent licking and lifting the paw post-injection was scored in 5-min 
bins offline. To minimize potential acute effects of exercise on behavior48,65, the formalin test 
was performed at least 16 hr after the final 2 hr training session, and at least 4 hr after the final 
overnight training session.  
 
Inverted screen test  
To evaluate muscle strength, mice were allowed to grasp onto a mesh grid. The grid was 
then inverted until mice were upside-down and the latency to fall recorded, using a cut off 
latency of 120 sec. Two trials were performed with at least 1 hr of rest allowed between trials.3 
 
Dissociating DRG neurons  
Mice were sacrificed via live decapitation and lumbar (L) dorsal root ganglia (DRG) 3-5 
were dissected from control and exercise trained mice. DRG were incubated in papain (45U) for 
20 min, rinsed, and incubated with collagenase (4.5 mg/200 µL) for 20 min. DRG were triturated 
to dissociate neurons and filtered with a 40 µm mesh filter. The dissociated cells were plated on 
poly-D-lysine/collagen coated glass coverslips and were tested 12-24 hr after plating.  
 
Electrophysiology  
Whole-cell recordings were made in current clamp on cells 20-30 µm in diameter to 
increase the likelihood of recording from nociceptive neurons. Fire polished glass pipettes were 
pulled using a P-97 micropipette puller (Sutter Instrument Company), and open tip resistances 
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ranged from 2.0-7.0 MΩ. Pipettes were filled with internal recording solution consisting of (in 
mM): 120 K+ gluconate, 5 NaCl, 2 MgCl2, 0.1 CaCl2, 10 HEPES, 1.1 EGTA, 4 Na2ATP, 0.4 
Na2GTP, 15 phosphocreatine; pH=7.3, 291 mOsm. While recording, cells were continuously 
perfused with room temperature external solution consisting of (in mM): 145 NaCl, 3 KCl, 2.5 
CaCl2, 1.2 MgCl2, 10 HEPES, 7 glucose, adjusted to pH 7.4 with NaOH. The series resistance 
of each recording was less than 20 MΩ. Patchmaster software (Heka Instruments Inc.) 
controlling an EPC10 USB amplifier (Heka Instruments Inc.) was used to record from neurons. 
Only neurons with a resting membrane potential more negative than -45 mV were included in 
data analysis.  
 
Spared nerve injury model 
Throughout surgery, mice were maintained under isofluorane anesthesia. A skin incision 
was made and the biceps femoris muscle was separated to expose the branches of the sciatic 
nerve. Without manipulating the sural nerve branch, the common peroneal and tibial braches 
were ligated with 6-0 silk suture and approximately 1 mm of nerve was removed distally.25 The 
wound was closed in layers and mice were monitored for signs of distress and allowed to 
recover post-operatively on a heating pad prior to returning to their home cages. Surgical 
procedures were approved by the Washington University in St. Louis DCM (Protocol Number: 
20130147).   
 
Gastrocnemius weight 
The gastrocnemius muscle was excised by cutting proximally from medial and lateral 
condyles of the femur and distally at the calcaneal tuberosity.73 Tissue was promptly weighed 
after dissection to obtain muscle wet weight. 
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Immunohistochemistry and hindpaw innervation  
After sacrificing animals with a rodent ketamine euthanasia cocktail, plantar hindpaw 
skin was excised and immersion fixed for 2-6 hr in 15% picric acid/2% paraformaldehyde at 4°C, 
washed in PBS, and cryoprotected in 30% sucrose. Hindpaw skin was sectioned at 30 µm 
perpendicular to the skin’s surface. To stain hindpaw skin, the primary antibodies rabbit anti-BIII 
tubulin 1:1000 (Covance PRB-435P) and goat anti-rat CGRP 1:400 (AB Serotec 1720-9007) 
were visualized using donkey anti-rabbit Alexa-fluor 555 1:200 (Invitrogen A31572) and donkey 
anti-goat Alexa-fluor 488 1:350 (Invitrogen A11055), respectively. Images were captured using 
an upright epifluorescent microscope (Nikon 80i, CoolSnap ES camera). MetaMorph software 
(Molecular Devices, LLC) was used to measure dermal-epidermal border length, and labeled 
intraepidermal fibers were counted and averaged from 5 nonsequential sections per animal. 
Intraepidermal nerve fiber (IENF) density is reported as number of fibers/100 µm dermal-
epidermal border.  
 
Epidermal thickness 
The vertical distance from the dermal-epidermal border to the outermost granular cell 
layer – visualized via DAPI staining – was measured at 5 separate points at 50 µm intervals to 
obtain the average thickness of each section from which IENFs were counted.  
 
Statistical analyses 
Data were analyzed using GraphPad Prism software (GraphPad Software, Inc.) and are 
presented as mean ± SEM. Withdrawal latencies and thresholds are normalized to baseline 
values obtained prior to exercise training or SNI. Data comparing the effect of exercise training 
as well as formalin responses over time were analyzed with a Student’s t-Test. A two-way 
repeated-measures (RM) analysis of variance (ANOVA) was used to analyze the effect of SNI 
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and exercise training on mechanical thresholds. SNI muscle strength, wet weight, innervation, 
and epidermal thickness were compared to uninjured controls by a one-way ANOVA. In all 
analyses, a Bonferroni test was used to correct for multiple comparisons.  
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4.4 Results 
Nociceptive thresholds were unaltered in uninjured, exercise trained animals 
To determine whether exercise training alters the nociceptive thresholds of uninjured 
mice, we gave mice access to running wheels for 2 hr a night, 5-6 nights a week, for 1-4 weeks. 
There was an average nightly running distance of 1.5 ± 0.1 km across cohorts. We are confident 
that the control and exercised animals differ solely in exercise training because during running 
sessions, controls experienced the same environmental enrichment and social isolation as 
exercised animals, but were unable to run on the locked wheel. In this regard, voluntary wheel 
running allows for more comprehensive control groups than forced exercise paradigms.  
Nociceptive thresholds were measured in uninjured mice at least 12 hr after the 
conclusion of training sessions to minimize the potential short-term effects of exercise on 
behavior.48,65 Following 1, 2, or 4 weeks training, cold sensitivity thresholds of exercised mice 
measured by the cold plantar assay remained unchanged when compared to controls (Fig. 1A). 
Similarly, noxious heat withdrawal latencies were unchanged in the Hargreaves test after up to 
4 weeks of exercise training (Fig. 1B).  Heat sensitivity was also tested using the hot plate test, 
which incorporates supraspinal processing of nociceptive stimuli.15,60 Latency to response to a 
55°C hot plate was not different between control and exercise trained mice (Fig. 1C). Lastly, 
exercise training did not alter mechanical withdrawal thresholds in the von Frey test (Fig. 1D).  
 
Sensory neuron excitability was unchanged following exercise training  
Increased excitability of DRG neurons has been shown to underlie hypersensitivity in a 
number of pain states.11,47,55 To determine whether exercise affects membrane and cell 
excitability properties in an uninjured context, whole-cell patch clamp electrophysiology was 
performed on dissociated L3-L5 DRG neuron cultures obtained from exercise trained and 
control animals within 24 hr of culturing (Fig. 2A). Recordings were performed on small diameter 
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neurons ranging from 20-30 µm to increase the likelihood of recording from nociceptive 
neurons.  
Consistent with behavioral experiments, 1-4 weeks of voluntary exercise training did not 
alter any of the membrane or cell excitability properties analyzed (Table 1). Resting membrane 
potential was unchanged in exercise trained animals as compared to controls (Fig. 2B). In 
current clamp, step (Fig. 2C) and ramp (Fig. 2D) current injections were used to analyze 
excitability properties. Rheobase, the current required to elicit an action potential, in response to 
Figure 1. Exercise training did not alter thermal or mechanical sensitivity of uninjured animals. (A) 
Following 1, 2, or 4 weeks of exercise training, paw withdrawal latencies in the cold plantar assay remained 
unchanged in exercise trained versus control mice, n=6-11. (B, C) Withdrawal latencies to noxious heat 
stimuli of exercise trained and control mice were equivalent in both Hargreaves and hot plate tests, n=9-15 
and 9-10, respectively. (D) Mechanical withdrawal thresholds were similarly unchanged by exercise, n=9-
15. Withdrawal latencies and thresholds are normalized to baseline values obtained prior to exercise 
training. Data are presented as mean ± SEM. Student’s t-Test, Bonferroni correction for multiple 
comparisons.  
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either step (Fig. 2E) or ramp (Fig. 2F) current injections were similarly unaffected by 1-4 weeks 
of wheel running. The number of action potentials in response to step and ramp current 
injections 2 and 3 times rheobase were also quantified to investigate if differences in excitability 
were apparent at higher stimulus intensities. Exercise training for 4 weeks did not change DRG 
excitability in response to these stimuli (Fig. 2G, H). Similar results were observed after 1 and 2 
weeks of exercise training. Overall, DRG membrane and excitability properties were unaffected 
by exercise in an uninjured context.  
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Acute inflammatory pain responses were not changed by exercise training  
Forced exercise has previously been shown to reduce formalin-induced spontaneous 
pain behavior.50 We asked whether voluntary exercise (pre-training) similarly attenuates acute 
inflammatory pain responses. Formalin was administered approximately 16 hr after the final 
exercise session and spontaneous nocifensive behavior was recorded. Mice that received 
wheel access for 2 hr/night for 1-4 weeks displayed the same biphasic response to formalin as 
controls (Fig. 3A-C). To examine whether an increased dose of wheel running could affect acute 
inflammatory pain responses, exercise training was extended to 12 hr/night. On average mice 
ran 9.9 ± 1.2 km during 12 hr wheel running sessions. This distance is comparable to37 if not 
greater than31,66 distances reported by studies in which mice received home cage wheel access.   
Again, exercise for 2 weeks prior to testing did not influence formalin-induced spontaneous 
behavior (Fig. 3D). Formalin injections took place 4-6 hr after completion of the final 12 hr/night 
Figure 2. Exercise training did not alter DRG neuron membrane or excitability properties of uninjured 
animals. Whole-cell patch clamp electrophysiology was performed on small-diameter cultured lumbar DRG 
neurons, N=2-3 animals. (A) An example of a patched neuron approximately 23 µm in diameter. (B) Resting 
membrane potential was unaltered by exercise training for 1, 2 or 4 weeks, n=13-25. Representative traces of 
action potentials elicited by step (C) and ramp (D) current injections of 1 to 3 times rheobase. A negative 
stepwise current was used to determine input resistance (Rin). Scale bars represent 20 mV and 100 ms. 
Rheobase in response to both step (E) and ramp (F) current injection was also unchanged by exercise, n = 
13-25 and 7-23, respectively. The number of action potentials elicited by step (G) and ramp (H) current 
injections 2 and 3 times rheobase was unaffected by 4 weeks of exercise training, n=22-25 and 20-23, 
respectively. Data are presented as mean ± SEM. Student’s t-Test, Bonferroni correction for multiple 
comparisons. 
Table 1. Membrane and action potential parameters of lumbar DRG neurons from control and 
exercise trained animals  
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exercise session. For each duration and dose of exercise tested, the cumulative time spent 
licking and lifting the hindpaw in the first (0-10 min) and second (11-60 min) phases of the 
formalin test were not different between exercise trained and control mice (Table 2).  
 
 
Figure 3. Exercise training did not attenuate nocifensive responses to acute inflammatory pain. (A-C) 
Wheel access for either 2 hr/night for 1 to 4 weeks, n=5 or (D) 12 hr/night for 2 weeks, n=4-6 prior to the 
formalin test did not reduce time spent licking or lifting the hindpaw during the first 60 minutes following 
intraplantar injection of 2% formalin. Data are presented as mean ± SEM. Student’s t-Test, Bonferroni 
correction for multiple comparisons.  
 
Table 2. Cumulative time spent licking and lifting the hindpaw during Phase I and II of the formalin test. 
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Exercise training did not improve mechanical hypersensitivity or muscle wasting following 
peripheral nerve injury 
The SNI rodent model of 
neuropathic pain produces prolonged 
and robust mechanical hypersensitivity in 
the ipsilateral hindpaw.25,30 Forced 
exercise has been shown to reverse 
mechanical hypersensitivity in other 
peripheral nerve injury models including 
chronic constriction injury and spinal 
nerve ligation.20,21,67 We asked whether 
voluntary wheel running could similarly 
reverse mechanical hypersensitivity 
caused by SNI.  
Unilateral SNI produced a 
significant reduction in mechanical 
withdrawal thresholds relative to baseline 
(Two-way RM ANOVA: SNI, 2 hr/night 
p<0.0001, SNI, 12 hr/night p<0.0001) 
(Fig. 4). Once the development of 
mechanical hypersensitivity was verified 
on post-operative days (POD) 3 or 4 and 
6 or 8, we began exercise training mice 
on POD 8-10 to determine if voluntary 
exercise could reverse nerve injury-induced mechanical hypersensitivity. After each week of 
Figure 4. Exercise training did not improve SNI-
induced mechanical hypersensitivity. (A, B) SNI 
gave rise to a significant reduction in mechanical 
withdrawal thresholds of the ipsilateral hindpaw in both 
SNI, control and SNI, exercise groups on POD 3/4 and 
6/8 relative to baseline values (dotted line) (SNI, 2 
hr/night p<0.0001, SNI, 12 hr/night p<0.0001, n=7-8 and 
5-7, respectively). When initiated 8 to 10 days post-op, 
2 weeks of exercise training for either 2 hr (A) or 12hr 
(B) per night did not reverse SNI-induced mechanical 
hypersensitivity. Mechanical withdrawal thresholds were 
tested at one-week increments after exercise began. 
The one-week time point was on POD 14,15, or 16. The 
two-week time point was on POD 21, 22, or 23. Data 
are presented as mean ± SEM. Two-way RM ANOVA, 
Bonferroni correction for multiple comparisons.  
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training, mechanical withdrawal thresholds were tested within 3 (12 hr/night group) to 12 hr (2 
hr/night group) of the last training session. The one and two week post-training von Frey testing 
time points ranged from POD 14-16 and POD 21-23 across cohorts, respectively. Neither 2 
hr/night (Fig. 4A) nor 12 hr/night  (Fig. 4B) of exercise training for 2 weeks improved SNI-
induced mechanical hypersensitivity. 
The selection of a voluntary wheel running paradigm in the current study gave rise to the 
concern that nerve-injured mice would exercise much less, if at all, compared to uninjured mice. 
Such activity impairment would decrease the likelihood of observing exercise-induced 
improvements following SNI. However, quantification of weekly running distances indicates that 
SNI mice ran equivalent distances to uninjured animals each week of training when sessions 
were either 2 or 12 hr/night (Table 3). These findings eliminate concerns about significant 
differences in exercise dose between injured and uninjured mice.  
 
In addition to hypersensitivity, sciatic nerve injury is associated with denervation, 
atrophy, and in turn muscle weakness.10,73 Exercise following sciatic nerve injury can enhance 
muscle reinnervation, as well as grip strength and hindlimb motor function.8,9,21,44 We tested if 
muscle strength is improved in SNI mice that were exercise trained for 12 hr/night for 2 weeks 
using the inverted screen test.3 In trial one, both SNI, control and SNI, exercised mice had a 
shorter latency to fall than uninjured control mice that did not reach statistical significance (Fig. 
5A). In trial two, latency to fall of both SNI groups was significantly shorter than uninjured, 
control mice (One-way ANOVA: p=0.0002). While mean latency to fall of SNI, exercise animals 
Table 3. SNI did not depress weekly voluntary wheel running distances.  
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was longer than that of SNI, control animals, the difference is not statistically significant. 
Interestingly, neither SNI group exhibited a training effect between trials, which may be due to 
muscle atrophy. We found that SNI mice did not use the injured hindpaw to grip the screen. 
Consistent with this possibility, we did not find that muscle strength was improved following 
exercise training in uninjured animals. However, we used a cutoff latency of 120 sec, which may 
have masked potential effects of exercise on inverted screen performance in longer 
experimental trials. A previous study found that 8 weeks, but not 5 days, of home cage wheel 
access increases both forepaw and hindpaw grip strength in mice.66  
 
Figure 5. Exercise training did not 
reduce nerve injury-induced muscle 
wasting. (A) The inverted screen test of 
muscle strength was performed on mice 
3 weeks (POD 21/22) after injury with a 
cut off latency of 120 sec (dotted line). 
SNI mice had a shorter latency to fall 
than uninjured mice in Trial 2 only 
(p=0.0002). Despite exercise training for 
12 hr/night for 9 nights, latency to fall of 
SNI, exercise mice was not improved 
compared to SNI, control mice, n=6-8. 
(B) By POD 25 SNI gave rise to a robust 
reduction in ipsilateral gastrocnemius 
muscle wet weight (p<0.0001), which 
was unchanged by exercise, n=6-8. 
Compared to uninjured controls, 
gastrocnemius muscle wet weight of 
uninjured, exercise mice was significantly 
reduced in the ipsilateral (p<0.01), but 
not the contralateral hindlimb. Data are 
presented as mean ± SEM.  **p<0.01, 
***p<0.001, ****p<0.0001, One-way 
ANOVA, Bonferroni correction for 
multiple comparisons. 
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To test whether voluntary wheel running improved muscle atrophy following SNI, we 
measured gastrocnemius wet weight. On POD 25, we observed a significant reduction in 
ipsilateral gastrocnemius muscle wet weight in SNI mice compared to uninjured controls (One-
way ANOVA: p<0.0001), while no change was observed in the contralateral muscle (Fig. 5B). 
Wheel running for 2 weeks, 12 hr/night did not reduce gastrocnemius muscle wasting. We 
observed a significant reduction in wet weight of the ipsilateral (One-way ANOVA: p<0.01), but 
not contralateral gastrocnemius, of uninjured, exercised mice compared to uninjured controls 
(Fig. 5B). A previous report indicates gastrocnemius wet weight is unchanged by forced or 
voluntary exercise in an uninjured context.52 
 
Hindpaw epidermal innervation and thickness were not changed by exercise training in 
uninjured or nerve-injured animals  
Voluntary wheel running has been shown to prevent increases in peptidergic IENF fiber 
density in a mouse model of prediabetic neuropathy.38 We investigated whether wheel running 
changes IENF density or fiber phenotypic distribution in uninjured and SNI animals.  
To determine if exercise training alters total IENF density, peripheral nerve fibers in 
hindpaw skin sections were identified by the neuron-specific marker βIII tubulin (Fig. 6A, red). 
Hindpaw innervation was further examined using a CGRP antibody as a marker of peptidergic 
fibers (Fig. 6B, red). IENF were defined as those fibers crossing the dermal-epidermal border, 
which was visualized with DAPI (Fig. 6A, B, blue). Quantification of total IENF density in 
hindpaw skin indicated no difference between control mice and mice exercise trained for 1-4 
weeks, 2 hr/night (Fig. 6C). The typically sparse CGRP+ IENF density relative to total IENF 
density was similarly unchanged by exercise at any time point (Fig. 6D).  
SNI causes marked denervation of the center aspect of plantar hindpaw skin within two 
weeks that begins to recover about 5 weeks after injury.33 To determine if exercise reduces this 
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denervation, center hindpaw total IENF density was quantified with βIII tubulin after two weeks 
of exercise, 25 days post-SNI. IENF density of SNI animals was significantly reduced compared 
Figure 6. Exercise training did not alter hindpaw epidermal innervation or thickness in uninjured or 
SNI animals. (A, B) 30 µm sections of plantar hindpaw skin were stained with βIII tubulin (red) and CGRP 
(red) to quantify total and peptidergic IENF density, respectively. Arrowheads indicate IENF. DAPI (blue) 
staining was used to visualize the granular cell layer of the epidermis and measure epidermal thickness. (C, 
D) Both total (βIII tubulin+) and peptidergic (CGRP+) IENF density were unchanged by 1-4 weeks of exercise 
training in uninjured mice, n=4-6. Student’s t-Test. (E) 25 days after injury, a significant reduction in total (βIII 
tubulin+) IENF density was observed in SNI, control mice compared to uninjured controls (p<0.0001, n=4). 
Exercise training for either 2 or 12 hr per night for 2 weeks did not improve hindpaw epidermal innervation 
following SNI. One-way ANOVA. (F) Epidermal thickness was unchanged by 1-4 weeks of wheel running in 
uninjured mice, n=4-6. Student’s t-Test. (G) Compared to uninjured controls, SNI, control hindpaw skin 
trended towards epidermal thinning that was unaffected by 2 or 12 hr/night of wheel running for 2 weeks, n=4. 
One-way ANOVA. In panels E and G, mean and SEM of 2 week, 2 hr/night uninjured, controls are 
represented by sold and dashed lines, respectively. Data are presented as mean ± SEM.  In all statistical 
analyses, a Bonferroni test was performed to correct for multiple comparisons.  
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to uninjured controls (One-way ANOVA: p<0.0001) (Fig. 6E). However, wheel running for either 
2 hr/night or 12 hr/night for 2 weeks did not improve IENF density of the ipsilateral hindpaw.  
Intraepidermal fibers aid in the maintenance of the epidermis, and epidermal thinning is 
a consequence of denervation.6,33,53,68 Therefore, epidermal thickness was also quantified 
alongside IENF density. Epidermal thickness was measured as the vertical distance from the 
dermal-epidermal border to the outermost granular cell layer. In uninjured mice, 1 to 4 weeks of 
exercise training did not give rise to changes in epidermal thickness (Fig. 6F). In hindpaw skin of 
SNI, control mice, epidermal denervation was accompanied by epidermal thinning compared to 
uninjured controls, though the deficit did not reach statistical significance (Fig. 6G). Exercise for 
2 weeks did not prevent SNI-induced epidermal thinning. This result was expected as recovery 
of epidermal thickness after nerve injury is thought to be the product of reinnervation19,53, and 
exercise did not reduce SNI-induced denervation. 
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4.5 Discussion 
We investigated the analgesic potential of voluntary wheel running in the contexts of 
acute inflammatory pain and neuropathic pain. We have shown that voluntary wheel running is 
not effective in attenuating formalin-induced nocifensive behavior or in improving SNI-induced 
mechanical hypersensitivity, muscle wasting, or skin denervation. We have also demonstrated 
that voluntary exercise training of uninjured animals does not cause changes in nociceptive 
thresholds, DRG excitability, or hindpaw innervation and epidermal thickness.  
We report a lack of an effect of voluntary exercise training on nociceptive thresholds of 
uninjured animals. In contrast, Mathes et al. demonstrated significantly lower radiant heat tail 
flick response latencies, an end point we did not evaluate, following voluntary exercise in rats.54 
However, thermal and mechanical hindpaw withdrawal thresholds were unchanged in rats 
following forced swim training and in mice that had home cage running wheel access.64,66 Our 
findings, along with previous studies reporting no effect of voluntary exercise on nociceptive 
thresholds in uninjured rodents, are consistent with human studies that have demonstrated 
basal pain thresholds are usually unchanged in athletes compared to non-athletes.35,69 These 
data suggest that nociceptive thresholds are tightly regulated in an uninjured context to protect 
organisms from tissue damage without causing withdrawal from benign stimuli.  
The finding that voluntary exercise training improves neither acute inflammatory pain 
responses nor recovery from peripheral nerve injury is in contrast to much of the existing 
literature. For instance, Kuphal et al. report that extended swimming for 9 days attenuates 
formalin-induced spontaneous pain.50 Further, forced treadmill running has been shown to 
reverse thermal and mechanical hypersensitivity following both peripheral nerve and spinal cord 
injury.8,20,21,26,67  
A number of possible explanations may underlie our observation that exercise is not 
analgesic in the context of acute inflammatory and nerve injury-induced pain. Foremost, the 
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current study differs from much of the existing literature due to the use of voluntary as opposed 
to forced exercise, which is reportedly more stressful.16,46 For example, in a study conducted by 
Leasure and Jones, forced but not voluntary wheel running increased both anxiety-like behavior 
in the open field test and emotional defecation.52 Moving animals in and out of running wheel 
cages is a potential source of stress. However, in our study, both control and exercise mice 
were transferred to running wheel cages during exercise periods. The two groups therefore 
differed only in exercise training because control mice were provided with locked running 
wheels. As training progressed, we observed noticeably fewer fecal pellets at the end of each 
session, suggesting that mice were not chronically stressed when placed into their individual 
cages. Importantly, cages of exercised mice were visibly cleaner than that of control mice, 
implying that voluntary exercise may have exerted an anxiolytic effect in our paradigm, as 
reported by others.7,32,61 Collectively, our results indicate that the analgesic effect of exercise is 
potentially dependent on the nature of the exercise paradigm. Definitive proof that the different 
effects of voluntary versus forced exercise are related to stress will require additional 
investigation.  
Another variable that could account for the differential effects of various exercise 
paradigms is exercise intensity. High intensity exercise has been shown to be more effective 
than low intensity exercise in reversing nerve injury-induced mechanical hypersensitivity in 
rats.67 In our study, it is possible that voluntary wheel running is not of sufficient intensity to 
induce the physiological adaptions required to attenuate acute inflammatory pain or reverse 
SNI-induced mechanical hypersensitivity. However, voluntary wheel running has been shown to 
induce similar physiological adaptions as forced exercise paradigms that are effective in 
attenuating pain. Examples of these adaptions include increased expression of endogenous 
opioids and heat shock protein 72, as well as altered expression of growth 
factors.1,2,4,5,18,37,42,63,67 In addition, one study found that wheel running of comparable distance to 
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that observed in our study normalized behavioral hypersensitivity associated with pre-diabetic 
neuropathy.37 These findings suggest that the exercise intensity of our paradigm is sufficient to 
engage the adaptive mechanisms contributing to exercise-induced analgesia. Other differences 
between our study and previous work such as social isolation and stress are more likely to 
contribute to the different outcomes.  
Our study is the first to investigate the effects of exercise on SNI-induced neuropathic 
pain. While previous studies have shown that voluntary wheel running improves pain-like 
behavior in mouse models of chronic muscle pain and prediabetic neuropathy, voluntary wheel 
running failed to improve SNI-induced mechanical hypersensitivity in our hands.38,66 Our results 
suggest that voluntary exercise-induced analgesia may be specific to certain types of 
neuropathies. The absence of exercise-induced improvements in our study may be due to the 
severe – and perhaps less modifiable – nature of SNI, in which ligation of the common peroneal 
and tibial nerves results in marked denervation of the hindpaw. Context-specific benefits of 
exercise have also been observed clinically. For example, aerobic exercise improves quality of 
life only in some type II diabetes patients, who often suffer from diabetic peripheral 
neuropathy.27,41 It is also worth noting that clinically, improvements in quality of life do not 
necessitate improved pain ratings.51 Rodent pain behavioral assays such as von Frey rely on 
nociceptive withdrawal thresholds as opposed to an endpoint that more comprehensively 
reflects a global pain experience. It is possible that voluntary exercise training can improve 
quality of life of nerve-injured mice. Efforts have been made to develop assays that more 
appropriately reflect clinical pain, but developing non-reflexive pain measures for rodent nerve 
injury models has proven to be difficult.36,70    
  Another distinguishing quality of SNI is that after injury von Frey testing occurs on the 
lateral aspect of the hindpaw, which is solely innervated by the spared sural nerve.25 Thus, we 
tested the sensitivity of uninjured fibers – though perhaps in an injured environment. Other 
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rodent nerve injury models such as spinal nerve ligation and chronic constriction injury test 
hindpaw regions innervated by a combination of uninjured and injured afferents.11,24,55 
Therefore, it is possible that exercise preferentially attenuates injury-induced dysfunction in 
injured nerve fibers.  
The timing of exercise intervention relative to nerve injury may also contribute to the lack 
of exercise-induced improvements following SNI. Because we were interested in whether 
exercise can reverse nerve-injury induced hypersensitivity, we chose to initiate exercise training 
on POD 8-10, once SNI-induced mechanical hypersensitivity was verified across multiple post-
injury time points. In contrast, prior studies initiated forced exercise training by POD 7.8,20,21,67 In 
these studies, exercise either attenuated the development of or improved existing mechanical 
hypersensitivity caused by peripheral nerve injury. Therefore, it is possible that our voluntary 
wheel running paradigm could improve SNI-induced mechanical hypersensitivity if training 
began closer to the time of injury, i.e. within one week. However, Stagg et al. tested if timing of 
exercise onset after spinal nerve ligation determines the time required to reverse mechanical 
hypersensitivity.67 When exercise was initiated either 1 or 4 weeks after injury, mechanical 
hypersensitivity was reduced within 3 weeks. The time at which exercise intervention must be 
initiated in order to recover nociceptive thresholds remains an interesting question.  
Our study evaluated the benefit of exercise in the prevention of acute formalin-induced 
pain and in the reversal of nerve injury-induced chronic pain. We have shown that our exercise 
paradigm does not prevent formalin-induced inflammatory pain. However, it is possible that our 
exercise paradigm would prevent the development of chronic pain induced by nerve injury. 
Inflammation-induced pain and nerve injury-induced pain share a number of common 
mechanisms; however, there are important differences.72 For instance, inflammatory pain is 
mediated through C fiber afferents, while neuropathic pain engages both C and Aβ fiber 
afferents.72 In addition, spontaneous pain is mediated by C fibers.28 It is unknown which fiber 
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types are functionally influenced by voluntary wheel running in our study. Therefore, while our 
exercise paradigm did not prevent acute inflammation-induced spontaneous pain, it may 
prevent the development or delay the onset of SNI-induced mechanical hypersensitivity.  
Lastly, it is also possible that exercise training of longer duration than our protocol of 2 
weeks is needed to observe improvements of mechanical hypersensitivity following SNI. 
Duration of exercise training required to improve rodent pain-like symptoms varies in different 
studies. For instance, following chronic constriction injury of the mouse sciatic nerve, forced 
treadmill running within the first week of injury reduced mechanical hypersensitivity.21 If treadmill 
running persisted for more than one week, however, improvements in mechanical thresholds 
were not observed. Similarly, in rats that underwent sciatic nerve transection, 2 weeks of 
treadmill running was sufficient to return mechanical thresholds to baseline.49 However, in other 
studies, the effects of exercise training are not apparent unless exercise persists for periods 
longer than 2 weeks after injury. Reductions in mechanical and heat hypersensitivity caused by 
spinal nerve ligation in rats did not develop until after the third week of treadmill running.67 
Further, Groover et al. first observed reversal of prediabetic neuropathy-induced mechanical 
and visceral hypersensitivity after 8 weeks of voluntary wheel running.38 
The injury models examined in our study largely represent cutaneous pain.  Even so, we 
cannot exclude injury to deep tissue or effects on deep tissue afferents (muscle) in either model. 
The SNI surgical procedure causes minimal damage to muscle; likewise, subcutaneous formalin 
injections could injure hindpaw muscle. However, the spontaneous nocifensive behavior 
resulting from subcutaneous formalin results from activation of cutaneous afferents and hindpaw 
von Frey is a measure of SNI-induced cutaneous hypersensitivity.17,59 Our study therefore 
evaluates the effect of voluntary exercise on cutaneous pain. Measures of deep tissue pain in 
SNI mice after exercise training, though not within the scope of our study, would address 
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whether voluntary exercise can reverse nerve injury-induced deep tissue pain, even though 
cutaneous hypersensitivity remains unchanged.  
To conclude, the current study demonstrates that voluntary exercise training of uninjured 
animals does not alter nociceptive thresholds, sensory neuron excitability, or hindpaw 
intraepidermal innervation.  We also demonstrate that voluntary wheel running fails to attenuate 
formalin-induced acute inflammatory pain and SNI-induced mechanical hypersensitivity, muscle 
wasting, and hindpaw denervation. When compared to existing literature, these results suggest 
that voluntary and forced exercise paradigms may have different analgesic potential. Further, 
the analgesic efficacy of voluntary exercise may be influenced by a number of variables 
including type of injury, timing of intervention, duration of exercise, and exercise intensity.  
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Over the past century, we have gained a remarkable understanding of the mechanisms 
underlying nociception, acute pain, and chronic pain. Unfortunately, this knowledge has not led 
to sufficient interventions to ease the suffering of the millions of people with chronic pain 
conditions. This dissertation describes and evaluates multiple approaches that could be used by 
basic scientists to test the translational potential of basic pain research findings. One approach 
includes the development and implementation of rodent behavioral assays that reflect the 
somatosensory as well as the cognitive and affective components characteristic of human pain 
(Chapter 2). Another approach entails utilizing human sensory neurons to assess whether 
mechanisms of peripheral sensitization blockade translate from rodents to human (Chapter 3). 
Lastly, we assess whether exercise-induced analgesia, a nonpharmacological intervention for 
pain relief, can be modeled in mice (Chapter 4). While these approaches for bridging the 
translational gap between rodent and human pain research were met with varied success, they 
raise important considerations for pain researchers.  
 
5.1 Can we use rodents to model human pain?  
In Chapter 2, we evaluated whether voluntary behaviors are interrupted in common 
rodent pain models. While chronic pain impairs physical and social activities and increases 
anxiety symptoms in humans8,11,13,25,32,37, we found that inflammation and nerve injury minimally 
interfere, if at all, with physical/social activity or anxiety-like behavior in mice. Overwhelmingly 
negative findings from our group and others22,35 have led some pain researchers to question 
whether we can or should use rodents to model human chronic pain and assess putative 
analgesics.2,21,36 Rodent models frequently fail to recapitulate the entirety of human disease 
states9, and it is perhaps unreasonable to expect so given different evolutionary pressures 
faced by rodents and humans. However, we support the continued use of rodents for preclinical 
pain research. Existing rodent models and pain-related behavioral assays of hypersensitivity 
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continue to provide valuable insights regarding the somatosensory aspects of chronic pain.16,38 
Therefore, the use of traditional measures of hypersensitivity in combination with newly 
developed pain-related measures of cognitive and motivational aspects of pain will provide an 
enhanced understanding of the translational potential of preclinical findings.   
 
5.2 Are innate rodent behaviors interrupted in pain models? 
 We assessed whether rodent models of persistent pain produce changes in voluntary 
behavior analogous to human behavioral changes seen in chronic pain conditions. However, an 
alternative approach in the development of non-reflexive measure of pain-like behavior is to 
determine whether innate rodent behaviors are altered following injury. For instance, impaired 
nest building, burrowing, and escape from bright light have all been suggested as pain-related 
suppressed behaviors in rodents and are broadly interpreted as indicators of reduced general 
well being.1,6,12,23,24 Importantly, these endpoints demonstrate predictive validity. Known 
analgesics such as NSAIDs or morphine can reverse inflammation- or nerve injury-induced 
suppression of nest building, burrowing, and bright light avoidance.1,12,24 In contrast, drugs that 
fail to provide analgesia clinically, such as kappa opioid receptor antagonists, do not.12,24 Further 
investigation is required to assess the utility of suppressed innate behaviors in preclinical pain 
research. For instance, the duration of inflammation-induced reductions in nest building appears 
equally short-lived (3-4 days) as the reductions we report in voluntary wheel running and gait in 
Chapter 2.24 In this regard, measures of suppressed innate rodent behavior may possess some 
of the same limitations as voluntary behavioral measures of pain. 
 Nevertheless, pain-related suppressed behaviors can provide information that otherwise 
goes undetected in tests of hypersensitivity. Suppression of innate behaviors does not correlate 
with mechanical hypersensitivity, and thus may reflect either spontaneous or global pain, rather 
than somatosensory thresholds alone.1,23 Further, measures of pain-suppressed behaviors 
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possess greater predictive validity than reflex withdrawal assays when assessing the efficacy of 
putative analgesics.1 In reflex/withdrawal tests, an increase in paw withdrawal threshold or 
latency is interpreted as a reduction in pain-like behavior. However, this could also reflect 
sedation or motor side effects caused by a drug. In contrast, the reversal of pain-related 
suppressed behaviors requires enhanced animal activity. Thus, endpoints such as burrowing 
decrease the likelihood of obtaining false-positive analgesic effects from pharmacological 
interventions. Taken together, measures of innate rodent pain-related suppressed behaviors 
represent an ethological approach to evaluating the somatosensory and affective components 
of pain in rodents. 
 
5.3 What terminology should be used to describe rodent pain-related behaviors? 
The recent efforts to develop voluntary, non-reflexive endpoints prompts pain 
researchers to evaluate the terminology used to describe rodent pain-like behavior. At present, 
it remains unclear whether behavioral changes observed after injury in rodents reflect pain, 
which is defined as a complex sensory, emotional, and cognitive experience. Thus, using the 
phrase “pain behavior” synonymously with mechanical and/or thermal hypersensitivity 
extrapolates behavioral observations and in turn anthropomorphizes rodents. This commonly 
used simplified terminology can be advantageous in that it increases the accessibility of pain 
research findings to those in other fields and in turn aids cross-sectional research, such as the 
interplay between drug addiction and chronic pain. Further, it is difficult to completely avoid 
anthropomorphizing terminology when discussing in vitro and animal models of clinical 
phenomena, such as peripheral analgesia in Chapter 3 and exercise-induced analgesia in 
Chapter 4. 
 The use of simplified terminology is problematic when striving to identify behavioral 
changes triggered by damage to the somatosensory sensory system, and a more precise 
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terminology for endpoints is therefore needed. This new terminology certainly requires 
consensus among pain researchers. We propose that the term “sensitization”, in reference to 
the mechanisms of peripheral and central sensitization thought to manifest in behavioral 
changes in humans and rodents, may be more appropriate than “pain”. Thus, throughout 
Chapters 2 and 4, we used the term “hypersensitivity” rather than “allodynia” or “hyperalgesia” 
to avoid anthropomorphizing the reduction in mouse mechanical and/or thermal paw withdrawal 
thresholds. Minor adjustments such as this in terminology used to describe behavioral changes 
associated with rodent injury models can offer substantial clarity as we continue to expand our 
repertoire of rodent pain-related assays.  
 
5.4 Which molecular mechanisms mediate peripheral analgesia in humans?  
 In Chapter 3 we demonstrated that mGlu2/3 receptor activation suppresses 
inflammation-induced TRPV1 sensitization in mouse sensory neurons. However, this 
mechanism of sensory neuron sensitization blockade did not translate in human sensory 
neurons. Which molecular mechanisms underlie this species difference in mGluR2/3 function is 
a compelling question. However, human tissue is a limited and valuable resource. We should 
therefore prioritize the use of human sensory neurons in studies that seek to understand human 
sensory neuron physiology rather than species differences.  
We previously showed that mGlu2/3 receptor activation blocks PGE2-induced membrane 
hyperexcitability in human sensory neurons.5 This observation establishes mGluR2/3 as 
putative peripheral analgesic targets in human. However, the underlying intracellular signaling 
pathway(s) engaged by mGluR2/3 that reduce hyperexcitability in human sensory neurons 
require further investigation. One potential mechanism includes enhanced activity of G protein-
coupled inward rectifying potassium channels (GIRKs). GIRKs, stimulated via Gβγ subunits of 
Gi proteins, are the major type of potassium channels activated by GPCRs.19 GIRK functional 
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expression has been demonstrated in rat sensory neurons and has been proposed to be 
required for peripheral opioid-induced analgesia by decreasing neuronal excitability.19,20,26 
Notably, GIRK mRNA and protein has also been detected in human sensory neurons.26,28 Like 
opioid receptors, group II mGluRs have been shown to functionally couple with GIRK channels 
in heterologous systems as well as in rodent and avian neurons.7,15,29,31 It would therefore be 
interesting to test whether the same functional coupling occurs in human sensory neurons and 
mediates mGluR2/3-induced suppression of membrane hyperexcitability. This could be 
achieved by determining whether inflammation-induced membrane hyperexcitability is occluded 
when a group II mGluR agonist is coapplied with a GIRK inhibitor. Experiments that aim to 
elucidate the intracellular signaling pathways activated in human sensory neurons by putative 
analgesics such as mGluR2/3 agonists can reveal unexpected species differences in sensory 
neuron physiology. Thus, using human sensory neurons to validate preclinical findings will 
improve our understanding of human physiology and inform the design of future clinical trials for 
pain relief.  
 
5.5 Does voluntary exercise reduce pain-like behavior in rodents?  
In Chapter 4, we evaluated whether voluntary wheel running could be used as a rodent 
model of exercise-induced analgesia with the intent of investigating the molecular mechanisms 
that mediate this clinically observed phenomena. Interestingly, we found that voluntary exercise 
did not alter stimulus-evoked paw withdrawal thresholds and/or nocifensive behaviors under 
basal conditions or in common mouse models of inflammation and nerve injury. At the time of 
publication, this was one of the first studies that utilized a voluntary rather than a forced exercise 
paradigm to investigate exercise-induced analgesia in rodents. Given that forced, but not 
voluntary, exercise increases activation of the hypothalamic-pituitary-adrenal axis14,33, our null 
findings prompt the question: If, and to what extent, do results of previous studies that utilized 
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forced exercise paradigms reflect a combination of exercise- and stress-induced analgesia? To 
answer this question, a side-by-side comparison evaluating the effects of forced versus 
voluntary exercise on rodent injury-induced pain-like behavior is required.  
While such a comparative study has not yet been completed, since the publication of our 
findings, multiple studies have demonstrated voluntary exercise-induced analgesia in rodents. 
For instance, voluntary wheel running prevents the development of hypersensitivity and/or 
weight bearing asymmetry induced by nerve injury, intra-articular inflammation, as well as 
chronic muscle pain.4,10,18 These recent observations contradict our findings; however, this 
contradiction may result from different experimental conditions between studies (discussed 
below). The benefits of exercise in nerve injury and chronic muscle pain models have been 
attributed to suppression of neuroinflammation at the site of injury and spinal cord in the form of 
either 1) decreased release of inflammatory cytokines10 or 2) a phenotypic switching of 
macrophages that enhances the release of anti-inflammatory cytokines.18 Interestingly, 
attenuation of nerve injury-induced mechanical hypersensitivity by forced treadmill running has 
been associated with decreased activation of spinal microglia that release proinflammatory 
cytokines.3,34 Thus, it is possible that voluntary and forced exercise engage the same molecular 
mechanisms to reduce pain-like behavior in rodents. Taken together, recent findings suggest 
that prior voluntary exercise is protective against the development of persistent pain-like 
behavior in rodents. This observation appears to extend to humans, as there is a lower 
prevalence of chronic pain in regularly exercising patient populations.17 For this reason, it has 
been suggested that chronic pain may represent a sedentary lifestyle-related disease.30  
Preventing the onset of chronic pain is an ideality. Instead, clinicians need interventions 
to treat established chronic pain conditions. Therefore, it is most relevant to assess whether 
exercise reverses pain-like behavior in rodent pain models. Unfortunately, little progress has 
been made in this regard. Since our publication, only two studies have evaluated voluntary 
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wheel running following nerve injury or intra-articular inflammation in rats.10,27 Interestingly, in 
contrast to our null findings, both studies show reversal of injury-induced hypersensitivity within 
2 weeks of wheel access, regardless of the onset of exercise. This discrepancy may be 
explained by a variety of differences in study design such as extent of wheel access (restricted 
versus homecage), injury model, subject species, etc. Thus, many questions remain regarding 
the analgesic potential of voluntary exercise in rodent models. Future investigations are also 
needed to determine whether this phenomenon is replicable and/or extends to additional pain 
models (i.e. visceral pain), as well as to gain insights regarding the molecular mechanisms that 
mediate voluntary exercise-induced analgesia after injury. Addressing these knowledge gaps 
may provide valuable insights regarding which clinical chronic pain conditions would be most 
improved by exercise interventions.  
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